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Identification of TRPV4 as a Regulator of Adipose Oxidative Metabolism, 
Inflammation and Energy Homeostasis by a Chemical Biology Approach 
 
Abstract 
 
PGC1α is a key transcriptional coregulator of mitochondrial biogenesis, oxidative 
metabolism and thermogenesis. We developed a quantitative high throughput 
screen to identify small molecules that can induce PGC1α expression in 
adipocytes. Small molecules antagonizing the TRPVs (Transient Receptor 
Potential Vanilloid), a family of ion channels, induced PGC1α expression in 
adipocytes. In particular, inhibition of TRPV4 increased expression of PGC1α, 
UCP1 and cellular respiration; conversely, chemical activation of TRPV4 
repressed this pathway. Blocking TRPV4 in cultured adipocytes also reduced the 
expression of multiple proinflammatory genes that are involved in the 
development of insulin resistance. These effects of TRPV4 were mediated by the 
activation of ERK1/2. Finally, mice with a null mutation for TRPV4 showed higher 
energy expenditure with no change in movement or food intake, and were 
protected from diet-induced obesity, adipose inflammation and insulin resistance.  
This study links TRPV4 to robust pathways that offer therapeutic potential in 
obesity and related metabolic diseases. 
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Introduction 
  
2 
 
Obesity and Energy Balance 
Obesity is clearly an epidemic in the United States. According to the CDC, about 
one third of Americans are clinically obese (with a BMI more than 30) and 
another third are overweight (BMI>25). This is not only a problem in North 
America, but is also becoming a global health concern. The WHO estimated that 
15% of the world population (1 billion) are overweight and more than 300 million 
are clinically obese. This trend in obesity is likely to contribute to the global public 
health burden, as obesity is a major risk factor for type 2 diabetes, cardiovascular 
disease, lipid disorders, and certain types of cancer (Haslam and James, 2005).  
Fundamentally, obesity is a disorder of energy balance. In any system, the net 
energy intake must be balanced by the sum of total energy expenditure and 
energy storage. In mammals, energy intake comes from the absorption of 
digested food. Energy expenditure can be divided into three large categories 
(Figure 1.1). First is obligatory energy expenditure, which includes the energy 
need for basal cellular function, growth and reproduction. The second is used for 
physical activities, mainly via skeletal muscle. The third category is used for 
generating heat to maintain body temperature, a process called thermogenesis. 
Thermogenesis can be further divided into two parts: obligatory and adaptive. 
The former is the heat generated from all biochemical processes in the body, 
because essentially all chemical reactions result in energy loss in the form of 
heat. The latter refers to heat production in response to environmental 
challenges such as cold or diet. 
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circuits involved in motivation and reward, they can also result in severe side 
effects. For example, a cannabinoid receptor 1 antagonist effectively reduced 
food intake and led to weight loss in obese patients, but was removed from the 
market due to an increased rate of suicide (Padwal and Majumdar, 2007). Other 
drugs have targeted lipid absorption in the intestine, but are associated with 
undesirable side effects and a lack of long-term efficacy (Melnikova and Wages, 
2006). Bariatric surgery is probably the most effective among all the approaches 
in this category, but its invasive nature and cost make it less attractive as a 
treatment for what is becoming a societal problem. 
Another way to alter energy balance is to increase energy expenditure. The 
portion used for basic cellular functions/growth, together with obligatory 
thermogenesis is difficult to alter by external intervention. Exercise, is a very 
popular approach for weight loss, and works by increasing energy output. 
Particularly when combined with diet, exercise can be very effective in altering 
the energy homeostasis and reducing body weight. However, patients have to 
follow a long-term exercise regimen to maintain the weight loss, which makes 
lasting success difficult (Wing and Phelan, 2005). Moreover, exercise is more 
useful for prevention or for patients in the early stages of obesity, as it can be 
challenging for morbidly obese patients or those with associated complications to 
exercise.  
The last, but probably most interesting component in the equation is the energy 
used for adaptive thermogenesis. The significance and physiological role of 
adaptive thermogenesis in response to diet remains controversial (Rothwell et al., 
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1983a; Rothwell et al., 1983b). In contrast, cold-induced, particularly non-
shivering thermogenesis has been well characterized at the cellular and 
organismal level in mammals. In response to cold, mammals need to quickly 
dissipate stored chemical energy, mainly from lipid, into large amounts of heat to 
keep the core temperature constant. In rodents and small animals, this process 
mainly takes place in the brown adipose tissue.  
Brown Adipose Tissue and Uncoupled Respiration 
White adipose tissue (WAT) is specialized for energy storage and usually has 
one large lipid droplet consisting of mainly triglyceride. White adipocytes have 
low mitochondrial content with limited oxidative capacity. In contrast, brown 
adipose tissue is specialized for dissipating chemical energy into heat. It has a 
large amount of mitochondria (the high cytochrome C content makes fat appear 
brown) and very high oxidative capacity. The most striking feature of brown 
adipose tissue is its capacity for uncoupled respiration in the mitochondria.  
The mitochondrion is the primary organelle in cellular energy metabolism and 
typically accounts for more than 90% cellular oxygen consumption (Rolfe and 
Brown, 1997). In mitochondria from most cell types, the processes of breaking 
down chemical bonds and electron transport are highly coupled to the production 
of ATP, to provide fuel for essentially all the biochemical reactions in a cell. The 
mitochondria in brown fat are unique in that instead of producing ATP, they are 
specialized to generate heat from chemical reactions. Specifically, brown fat 
expresses a unique protein called uncoupling protein 1 (UCP1) in the 
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mitochondrial inner membrane. UCP1 allows the protons in the intermembrane 
space from the electron transport chain to re-enter the mitochondrial matrix 
without going through complex V to generate ATP. The leak itself releases the 
energy from the proton gradient into heat. More importantly, this futile cycle 
accelerates the influx through the electron transport chain and upstream 
reactions (such as TCA cycle and beta-oxidation), in which all intermediate steps 
produce heat.  
It is clear that this uncoupling process is highly thermogenic, and also highly 
energy consuming by running fuel through futile cycles. In rats, for example, 
three grams of activated brown fat (1% of their body weight) can consume as 
much as 200% of the whole body basal metabolic rate (Foster and Frydman, 
1979). It is estimated that in humans, as little as 50 grams of activated brown fat 
is enough to consume up to 20% of the total metabolic rate (Rothwell and Stock, 
1983). Therefore, uncoupled respiration may provide a very powerful way to 
increase energy expenditure, and hence to alter the energy imbalance 
underlining obesity. 
A nonspecific chemical uncoupler was actually used for treating obesity back in 
the 1920s. 2-4-dinitrophenol (DNP) was effective at increasing energy 
expenditure and reducing adiposity in humans (Harper et al., 2008). However, 
the excess heat production induced by this nonspecific uncoupler led to fatal 
fever in some patients and eventually caused the removal of this compound from 
clinical use. Nevertheless, the early example of DNP treatment demonstrated the 
efficacy of targeting uncoupled respiration as a therapeutic for obesity. It is 
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conceivable that, if one could specifically target uncoupling in adipose tissues 
rather than causing proton leak in every cell in the body, therapy targeting this 
pathway might be safe and effective.  
Brown Adipose Tissue in Humans 
In rodents, brown adipose tissue’s role in defending from cold challenge and 
obesity has been well established. In humans, brown adipose tissue has been 
identified in infants at the interscapular region and thought to be important for 
maintaining body temperature. However, after a few months of life, most likely 
due to the decrease in surface-to-volume ratio, the interscapular brown fat 
gradually disappears. For a long time, it was believed that adult humans do not 
possess functional brown fat and that adaptive thermogenesis is presumably 
mediated by alternative mechanisms in other tissues, such as skeletal muscle.  
Several earlier reports suggested that “hot spots” were often identified around the 
neck and intercostal spaces near the spine of PET scans in patients (Hany et al., 
2002; Tatsumi et al., 2004; Weber, 2004; Yeung et al., 2003). This observation 
triggered investigators to look more carefully for the possible presence of brown 
fat in adults. In 2009, three independent groups reported the “re-discovery” of 
brown fat in adult humans by using fludeoxyglucose (FDG) in combination with 
PET/CT technologies (Cypess et al., 2009; van Marken Lichtenbelt et al., 2009; 
Virtanen et al., 2009). It is now clear that adult humans do have supraclavicular 
UCP1-postive, brown-like adipose tissue that can be activated by cold exposure. 
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The physiological role of these depots in thermogenesis and metabolism is still 
not clear at this point. 
Transcriptional Control of Brown Adipocyte Differentiation 
Although the morphology, function and developmental origin of white and brown 
adipocytes are distinct, their cellular differentiation (adipogenesis) is similarly 
controlled by a largely overlapping transcriptional network. The molecular 
mechanism of white adipocyte differentiation has been extensively studied since 
the 1990s, after the identification of the important roles of PPAR-γ (Peroxisome 
proliferator-activated receptor- γ) and C/EBPs (CCAAT/enhancer-binding 
proteins) in controlling this process (Farmer, 2006). Briefly, PPAR-γ is the master 
regulator of adipogenesis, and is both sufficient and required for the formation of 
brown and white adipocytes. C/EBPs coordinate this transcription cascade, with 
PPAR-γ to promote and maintain adipose differentiation.  
PPAR-γ is definitely necessary for brown fat differentiation (Rosen and 
MacDougald, 2006). However, when PPAR-γ was ectopically expressed in “naive” 
mesenchymal precursor cells, it drove the latter into white fat cells, suggesting 
there are additional cell type specific transcriptional components that specify the 
differentiation of brown adipocytes. This leads to the search for a brown fat 
specific co-activator of PPAR-γ. A brown fat-enriched co-activator of PPAR-γ, 
PGC1α (PPAR-γ coactivator-1α) was identified in 1998 using a yeast two hybrid 
system (Puigserver et al., 1998). Ectopic expression of PGC1α in mouse and 
human white adipocytes induced mitochondrial biogenesis and gave those cells 
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BAT-like thermogenic properties, such as increased expression of UCP1 and the 
deiodinase-2, with resultant higher cellular respiration (Puigserver et al., 1998; 
Tiraby et al., 2003) . Although PGC1α whole body knockout mice develop severe 
hypothermia when they are challenged with cold exposure (Leone et al., 2005; 
Lin et al., 2004), the thermogenic program in cultured PGC1α-/- brown 
adipocytes appeared to be preserved by the closely related coactivator PGC1β 
(Uldry et al., 2006) . Very recently, adipose-specific PGC1α knockout mice have 
been shown to have a defect in thermogenesis in adipose tissue and become 
more susceptible to metabolic disorders caused by a high fat diet (unpublished 
results). 
Forkhead box C2 (FOXC2) is another transcription factor that is highly expressed 
in adipose tissue. Overexpression of FOXC2 in white fat in a transgenic mouse 
model strikingly increased the expression of UCP1 and PGC1α, causing a brown 
fat-like phenotypic switch in white adipocytes. In a transgenic mouse model, this 
phenotypic change rendered the animal resistant to diet induced obesity and 
metabolic disorders (Dahle et al., 2002). The lack of enrichment of FOXC2 in 
brown adipose tissue indicates that FOXC2 is probably not required for 
specifying the development of brown fat. It has been suggested that FOXC2 
works by potentiating beta-adrenergic-cAMP-PKA signaling.  
On the other hand, several factors have been shown to negatively regulate 
brown fat differentiation and/or function. The RB (retinoblastoma protein) family 
members: pRB (Hansen et al., 2004) and p107 (Scime et al., 2005), the nuclear 
receptor LXRα (Wang et al., 2008), the nuclear receptor co-repressor RIP140 
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(Christian et al., 2005), and many other transcription factors such as IKKε 
(Chiang et al., 2009), fsp27(Toh et al., 2008), and twist-1 (Pan et al., 2009) have 
been shown to repress the expression of thermogenic genes particularly PGC1α 
and UCP1. Mice with deficiency in these genes have been reported to have a 
“browning” phenotype in white adipose tissue. However, the role of most of these 
genes in brown fat development remains to be further explored.  
PGC1α Co-activator 
PGC1α was originally identified as a coactivator of PPARγ in the control of the 
UCP1 promoter in brown fat cells (Puigserver et al., 1998). Subsequent work has 
illustrated that it binds to and coactivates most nuclear receptors as well as many 
transcription factors outside the nuclear receptor family (Handschin and 
Spiegelman, 2006). PGC1α plays a key role in mitochondrial biogenesis and 
oxidative metabolism in many tissues such as skeletal muscle and brown fat, 
linking mitochondrial biogenesis to the extracellular and extraorganismal 
environment.  
PGC1α gene expression is induced in brown adipose tissue by cold exposure 
and by agents that activate the β-adrenergic system. Genetic ablation of PGC1α 
resulted in impaired cold-induced thermogenesis in vivo and a diminished cAMP-
response in vitro (Lin et al., 2004; Uldry et al., 2006). Although PGC1α has a 
dominant role in thermogenesis, the loss of PGC1α did not affect the mass of 
brown adipose or the expression of many brown fat identity genes. Therefore, it 
is now believed that PGC1α functions as the central regulator of mitochondrial 
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biogenesis and thermogenesis in brown fat, but does not control its fate 
determination. This led to a subsequent search for brown fat determination 
factors that later identified PRDM16. 
PRDM16 
It has been noticed that precursors isolated from brown or white adipose tissue, 
through an unknown mechanism, ‘remember’ their identity even after being 
immortalized in vitro and cultured for many passages. For example, stromal-
vascular fraction cells from brown adipose tissue can be immortalized in vitro by 
transducing SV40 into these cells. When these transduced BAT-derived 
fibroblasts were induced to differentiate together with WAT derived fibroblasts 
under the exact same conditions, the former maintained clear brown adipocyte 
characteristics such as high thermogenic gene expression and robust cellular 
uncoupled respiration. This intrinsic difference in precursor cells led to the 
discovery of PRDM16 (PR-domain containing -16) as a brown fat determination 
transcriptional regulator (Seale et al., 2007). 
Ectopic expression of PRDM16 in mesenchymal fibroblasts or committed white 
precursors induced a robust brown adipose program. Overexpression of 
PRDM16 in a transgenic model potently induced brown characteristics in the 
white adipose tissue and rendered the mice resistant against obesity and insulin 
resistance (Seale et al., 2011). 
Interestingly and strikingly, depleting PRDM16 in brown fat precursors not only 
blocked brown fat adipogenesis, but drove these precursors to differentiate into 
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skeletal myocytes. Conversely, when PRDM16 was ectopically expressed in 
muscle precursors, it led to a robust brown fat differentiation in these cells. These 
results suggested that skeletal muscle and brown fat might have a very close 
developmental origin and that determination between these two cell fates might 
be controlled by PRDM16 (Seale et al., 2008).  
To determine the development origin of brown adipose tissue, a lineage tracing 
experiment was performed in vivo using myf5, a gene that was believed to be 
exclusively expressed in muscle precursors. Surprisingly, it was discovered that 
interscapular brown fat originated from a myf-5 positive lineage that gave rise to 
skeletal muscle (Lepper and Fan, 2010; Seale et al., 2008). Importantly, this myf-
5 positive lineage only gave rise to the “classical” interscapular brown fat depot, 
but not the emerging “brown fat-like cells” within white fat depots, in response to 
cold exposure or beta-agonist treatment. 
The Concept of Beige Fat 
Based on the lineage tracing with PRDM16, it is now known that there are two 
distinct kinds of brown fat cells. The classical type of brown fat is exemplified by 
the interscapular depot of rodents. These UCP1 expressing cells are derived 
from a muscle-like lineage that expresses Myf5/Pax7 during earlier development 
(Lepper and Fan, 2010; Seale et al., 2008). Pockets of UCP1-positive cells can 
also emerge in white fat depots under chronic exposure to cold or β-adrenergic 
stimulation (Cousin et al., 1992; Ghorbani and Himms-Hagen, 1997; Guerra et al., 
1998; Himms-Hagen et al., 2000; Xue et al., 2005) as well as chronic treatment 
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with PPARγ agonists or prostaglandins (Petrovic et al., 2010). These cells do not 
come from a myf5-positive lineage (Seale et al., 2008) and have been called 
“beige”, “brite” (brown in white), “ectopic brown”, “systemic brown”, or “recruitable 
brown” fat cells (Ishibashi and Seale, 2010; Petrovic et al., 2010). 
Obesity and Inflammation  
Obesity has been known as a risk factor for insulin resistance and type 2 
diabetes long before people understood the mechanistic connection between 
them. Over the past two decades, inflammation in adipose tissue associated with 
obesity has been appreciated as one of the most important factors linking 
increased adiposity and insulin resistance (Gregor and Hotamisligil, 2011; Horng 
and Hotamisligil, 2011). It was first discovered in 1993 that adipose tissue from 
obese mice expressed a higher level of TNF-α than adipose tissue from lean 
mice (Hotamisligil et al., 1993). Chronic, low-grade inflammation was identified to 
be present in adipose tissue from obese animals and humans (Hotamisligil et al., 
1995; Hotamisligil et al., 1996). TNF-α is a secreted factor which potently inhibits 
insulin signaling. It acts on adipose tissues as well as other metabolic tissues 
such as muscle and liver to cause systemic insulin resistance. Besides TNF-α, 
many other pro-inflammatory cytokines were later found to be increased in obese 
adipose tissues, including Interleukin 6 (IL-6), interleukin 1- β (IL-1β) and 
monocyte chemotactic protein-1 (MCP1) (Donath and Shoelson, 2011). These 
contribute to the vicious cycle that amplifies and sustains the inflammation in 
adipose and other tissues. 
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Inflammation and Insulin Signaling 
How inflammation affects insulin signaling has been intensively studied at the 
molecular level since the discovery of elevated TNF-α in obese tissues. Insulin 
receptors belong to the tyrosine kinase receptor family. In a simplified model, 
when insulin binds to its receptors, the receptors phosphorylate insulin receptor 
substrate proteins (IRS, 1-6) on tyrosine sites (Taniguchi et al., 2006; White, 
2002). This insulin stimulated tyrosine phosphorylation on IRS is believed to be a 
crucial step for insulin signaling in all insulin sensitive cells. Exposing cells to 
inflammatory cytokines, such as TNF-α, IL-6 and IL-1β, as well as free fatty acids 
can lead to serine phosphorylation on IRS proteins, which counteracts the 
tyrosine phosphorylation caused by insulin and therefore impaired insulin 
sensitivity. 
This inhibitory serine phosphorylation is mediated by various stress-sensitive 
kinases that can be activated by pro-inflammatory cytokines and fatty acids, such 
as p38MAPK (Jiang et al., 2004), ERK1/2(Engelman et al., 2000), JNK1/2 (Gao 
et al., 2004; Suganami et al., 2005) and IKKβ (Gao et al., 2004). Among them, 
JNK1/2 and IKKβ have been most intensively studied for their functions in 
adipose inflammation and insulin resistance. 
Stress-activated Kinases and NF-kB Signaling 
JNK1/ 2 can be activated by TNF-α, ER stress, oxidative stress and free fatty 
acids (Aguirre et al., 2000; Ozcan et al., 2004; Wellen and Hotamisligil, 2005), all 
of which are known to be elevated in the obese state. Indeed, JNK1/2 was 
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reported to be activated in both dietary and genetic obese mouse models 
(Hirosumi et al., 2002). Activated JNK1/2 leads to phosphorylation on IRS1 and 
hence inhibits insulin signaling (Gao et al., 2004; Ozcan et al., 2004). It also 
activates transcription factors such as ELK1, ATF2 (activating transcription factor 
2) and AP1 (Baud and Karin, 2001), which in turn further promote the expression 
of pro-inflammatory genes to amplify the vicious inflammation-insulin-resistance 
cycle. Mouse models with genetic JNK1 deficiency showed reduced adiposity, 
improved insulin sensitivity and became resistant to high fat diet induced insulin 
resistance (Hirosumi et al., 2002).  
Both ERK1/2 and p38MAPK can be activated by interleukin-1 and TNF-α 
(Engelman et al., 2000; Hernandez et al., 2004; Jager et al., 2007; Lee et al., 
2003). They both have been reported to be activated in obese animals (Bost et 
al., 2005; Jiang et al., 2004). The activated kinases also phosphorylate IRS1 and 
lead to decreased insulin sensitivity. ERK1-/- mice have been reported to have 
increased energy expenditure and are resistant to diet-induced obesity, although 
the effects on insulin resistance were confounded by differences in obesity and 
adipogenesis between the mutant and wild type mice (Bost et al., 2005). In a 
separate study, ERK1 deficiency partially rescued leptin-deficient (ob/ob) mice 
from insulin resistance by decreasing adipose inflammation (Jager et al., 2011). 
IKKβ is another important kinase that has a role in inflammation and the 
development of insulin resistance. It can be activated downstream of cytokine 
receptors such as the TNF-α receptor (Gao et al., 2003b), as well as by toll-like 
receptors (TLRs) that bind to free fatty acids and pathogens (Arkan et al., 2005; 
16 
 
Cai et al., 2005) . Besides directly phosphorylating IRS1 on serine sites, IKKβ 
also activates NF-kB signaling. The translocation of NF-kB from the cytoplasm to 
the nucleus ultimately leads to increased expression of many pro-inflammatory 
cytokines, including TNF-α. Heterozygous IKKβ knockout mice are partially 
protected from insulin resistance, at least in part due to its function in 
macrophages. Conversely, high-dose salicylates that inhibit IKKβ activity 
improved insulin sensitivity in animals and humans (Hundal et al., 2002; Yuan et 
al., 2001).  
Overall, adipose inflammation and insulin resistance form a feed-forward cycle. 
In obesity, elevated secretion of pro-inflammatory cytokines, together with other 
metabolic stresses (many of which are caused by insulin resistance) leads to the 
activation of stress-sensing kinases such as JNK1/2, ERK1/2 and IKKβ. These 
kinases, on one hand, directly mediate the inhibitory serine phosphorylation on 
insulin receptor substrates (IRS) to further exacerbate insulin signaling. On the 
other hand, pro-inflammatory signals also converge at transcription factors such 
as AP1 and NF-kB, eventually leading to increased expression of those pro-
inflammatory cytokines/adipokines which trigger this whole cascade in the first 
place. As obesity develops, this vicious cycle is continuously amplified and 
sustained, contributing to systemic insulin resistance and type 2 diabetes. 
The Initiation of Adipose Inflammation 
When TNF-α and inflammation was initially discovered in adipose tissue, it was 
believed that those inflammatory cytokines were secreted mainly from adipocytes 
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themselves. Later, it became clear that although adipocytes did secrete TNF-α 
and IL6, the majority of the cytokines from inflamed adipose tissue derived from 
the infiltrating immune cells (Weisberg et al., 2003; Xu et al., 2003). The 
presence of neutrophils, eosinophils and macrophages all have been reported in 
inflamed adipose tissue (Hotamisligil, 2006). While the role of other immune cells 
in adipose inflammation and insulin resistance is less clear, the importance of 
adipose tissue macrophages (ATM) has been well established over the last ten 
years. Macrophage infiltration is clearly associated with obese conditions and 
correlated with measures of insulin resistance, in both mice and humans. In 
severe obesity, these ATMs can make up to 40% of the cell population in 
adipose tissue and are a prominent source of pro-inflammatory cytokines such as 
TNF-α and IL6 (Weisberg et al., 2003; Xu et al., 2003).  
Despite the significant role of macrophages in secreting cytokines and mediating 
insulin resistance, there are very few macrophages in adipose tissue in lean 
animals or humans. This raises the question of what signals first attract 
macrophages into adipose tissue in the obese state. Intuitively, some unknown 
changes must have taken place during the expansion of adipose tissue, likely in 
the adipocytes, which then send signals to the monocytes and/or other circulating 
immune cells to recruit them into the adipose tissue. The exact cause of this 
initial recruitment is largely unknown. Adipocyte cell death, mitochondrial 
dysfunction and increased ROS production, hypoxia, ER stress and nutrient 
overflow (fatty acid flux) have all been suggested to be the mechanisms by which 
early macrophage recruitment is initiated (Sun et al., 2011).  
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Chemotactic Regulation 
Chemokines are small proteins that attract various immune cells, such as 
monocyte, neutrophils, T lymphocytes, basophils or eosinophils, from bone 
marrow or the circulation into tissues. They are characterized by their unique four 
highly-conserved cysteine residues: CXC chemokines which have two amino-
terminal cysteine residues separated by one amino acid; and CC chemokines 
whose two amino-terminal cysteine residues are adjacent. As the chemokines 
present in inflamed adipose tissues can produced by adipocytes or immune cells, 
the origin of these molecules in the obese state is difficult to determine. However, 
because chemokines are necessary for the attraction of immune cells, it is 
reasonable to speculate that in the early phase of inflammation, the initial 
recruitment of macrophages must involve chemokines from non-immune cells, 
such as adipocytes, before there are significant amounts of infiltrating immune 
cells. 
Many chemokines are associated with obesity and type 2 diabetes. In humans, 
increased MCP1 (CCL2), CXCL5 and CXCL8 have been shown to be associated 
with both obesity and diabetes. Others such as RANTES (CCL5), MCP3 (CCL7), 
MCP2 (CCL8), CCL11 and CCL13 have been reported to be elevated in obesity.  
In mouse models, CCL2-5, CCL11, CXCL11, CXCL5, CXCL8 and CXCL10 have 
been found to be secreted from adipocytes, and their increased expression was 
associated with obesity and insulin resistance (Sell and Eckel, 2009).  
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Among them, MCP1 (CCL2) has been most extensively studied. In vitro, 
expression and secretion of MCP1 is regulated by insulin, TNF-α and IL6, 
consistent with its regulation in vivo in the context of obesity and diabetes 
(Fasshauer et al., 2004). A transgenic model with MCP1 overexpression in 
adipocytes mimics the phenotypes seen in obesity: increased macrophage 
infiltration in adipose tissue, insulin resistance and liver steatosis (Kamei et al., 
2006). Conversely, studies using MCP1 deficient mice revealed that loss of 
MCP1 ameliorated adipose inflammation and insulin resistance in dietary or 
genetic obesity (Kanda et al., 2006). Consistent with the observations from the 
MCP1 knockout model (although there are conflicting results from other studies) 
(Inouye et al., 2007), one study using CCR2 (receptor for MCP1) knockout mice 
demonstrated that lack of CCR2 in high fat diet fed mice resulted in reduced 
macrophage infiltration, ameliorated inflammation and improved insulin sensitivity 
(Chen et al., 2005; Weisberg et al., 2006). However, the metabolic 
consequences of MCP1-CCR2 axis deficiency are relatively small, likely due to 
the redundancy between all the chemokines that attract monocytes. 
Other than MCP1, other chemokines have not been thoroughly studied using 
genetic models. The characterization has been limited to their associations with 
insulin resistance or obesity.  
TRPV Family Channels and TRPV1 Pharmacology 
Transient Receptor Potential (TRP) cation channels are a superfamily of sensory 
channels wildly expressed across almost every tissue and cell type. Based on 
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their structure and function, they were further divided into seven subfamilies: 
TRPC (Canonical), TRPV (Vanilloid), TRPM (Melastatin), TRPP (Polycystin), 
TRPML (Mucolipin), TRPA (Ankyrin) and TRPN (NOMP-C) (Nilius, 2007).  
TRPV1 (Transient Receptor Potential Vanilloid receptor 1), also known as the 
capsaicin receptor, is the first cloned member of the TRPV family (Caterina et al., 
1997). TRPV1 is a non-selective cation channel with calcium preference. Similar 
to other TRP family members, TRPV1 has a putative six-transmembrane domain 
and pore region located between the fifth and sixth transmembrane segments. 
As a nociceptor, TRPV1 can be activated by a range of physical and chemical 
stimuli, including capsaicin, heat (approximately 43°C), protons, bradykinin, 
nerve-growth factor, anandamide, prostaglandins, adenosine and ATP, 
polyamines and venoms from fish and insects (Szallasi et al., 2007).   
TRPV1 became a popular target for pain control for several reasons. First, the 
agents or physical stimuli that activate TRPV1 are those cause pain sensation in 
humans or rodents (Knotkova et al., 2008; Szallasi and Blumberg, 1999). TRPV1 
activity is indeed up-regulated in inflammatory conditions. Conversely, 
compounds that desensitize or antagonize TRPV1 alleviate pain-like behaviors or 
pain in rodents and human, respectively (Wong and Gavva, 2009). Moreover, 
TRPV1-/- mice showed attenuated thermal hypersensitivity after inflammation, 
indicating a role in mediating hyperalgesia (Caterina et al., 2000; Davis et al., 
2000). In contrast to conventional approaches that either inhibits the production 
of inflammatory mediators or block the transmission of pain, targeting TRPV1 
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provides a novel and promising way to prevent pain by directly antagonizing 
sensor.  
Because of this concept of manipulating TRPV1 for pain control, numerous 
efforts have been made to develop compounds that either directly antagonize 
this channel or desensitize it by using agonists. Particularly, several antagonists 
that have potent anti-hyperalgesic effects in animal models have been in clinical 
trials, including AMG517 (Amgen), AZD1386 (AstraZeneca), GRC6211 
(Glenmark/lily), JTS-653 (Japan Tobacco) and MK2295 (Merck/Neurogen) 
(Wong and Gavva, 2009). A common side effect of TRPV1 antagonists, at least 
in animal models, is that essentially all of them caused a transient hyperthermia 
in vivo (Romanovsky et al., 2009). Interestingly, this side effect seems to be “on 
target” as the hyperthermia was not seen when those compounds were given to 
TRPV1 deficient mice (Romanovsky et al., 2009).  
TRPV4 and Other TRPV family Members 
The relatively mild phenotype seen in Trpv1-/- mice in terms of temperature and 
pain sensing (Caterina et al., 2000), at least in the non-stimulated state, appears 
to contradict its prominent roles in these pathways suggested by in vitro and 
pharmacological studies. This suggests that there are other closely related 
TRPVs in the family. Other TRPVs are likely to compensate for the loss of 
TRPV1 during development, indicating a redundancy in this system. On the other 
hand, the specificity of pharmacological approaches is also usually limited. The 
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combination of these two factors probably accounts for the discrepancy between 
the genetic and pharmacological observations. 
There are six members in the TRPV family: TRPV1-6. While TRPV1-4 are 
thermosensitive, polymodal, calcium permeable but non-selective cation 
channels; TRPV5 and TRPV6 are highly selective for calcium and insensitive to 
temperature (Everaerts et al., 2010).  
TRPV4 is closely related to TRPV1 with a 40.9% sequence identity. It was first 
identified as an osmosensor (Liedtke et al., 2000).  Since then, many physical 
and chemical stimuli have been shown to activate TRPV4 (Nilius et al., 2004), 
including warmth (Guler et al., 2002; Watanabe et al., 2002), mechano-
stimulation (Gao et al., 2003a), endocannabinoids (Watanabe et al., 2003) and 
bisandrographolide A (BAA) (Smith et al., 2006). TRPV4 is widely expressed in 
many tissues, including kidney, lung, fat, bladder, brain, skin, brain, dorsal root 
ganglia, liver, testis and heart. Also, its expression is not limited to excitable cells 
but it is also present in non-excitable cells, such as epithelial cells, chondrocytes, 
and osteoclasts (Everaerts et al., 2010).  
Corresponding to its broad expression pattern, many functions of TRPV4 in 
various cells/tissues have been explored since its discovery. Among them, 
osmolarity sensing/regulation in CNS (Liedtke and Friedman, 2003), bone 
remodeling (Masuyama et al., 2008) and thermosensation (Lee et al., 2005) are 
the best characterized functions of TRPV4 based on a genetic TRPV4 deficiency 
model. In addition, other potential roles in epithelial cells, endothelial cells, 
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bladder urothelium and smooth muscle cells have been suggested in cellular 
models but the physiological importance of these roles required more in vivo 
studies (Everaerts et al., 2010). 
Notably, there are three recent studies linking TRPV4 mutations to human 
diseases. In one study, two heterozygous amino acid substitution mutations on 
TRPV4 (C946CT and G806A) resulted in familial scapuloperoneal spinal muscle 
atrophy (SPSMA) and Charcot-Marie-Tooth disease type 2C (CMT2C) in two 
unrelated families (Deng et al., 2010). The other study identified an additional 
heterozygous C946T mutation also causing SPSMA or CMT2C (Auer-Grumbach 
et al., 2010). The third study showed another two CMT2C-causing heterozygous 
mutations (C805CT and G806GA) in TRPV4 (Landoure et al., 2010). Despite the 
striking phenotype, however, the nature of these mutations is still controversial; 
as there are conflicting results as to whether these are gain-of-function or loss-of-
function mutations. Further study is needed to clarify the mechanism of these 
channelopathies. 
TRPs Function in Adipocyte Biology 
TRPs, particularly TRPV1, have been reported to function in adipocytes. 
Activation of TRPV1 by capsaicin has been reported to inhibit adipogenesis in 
3T3-L1 adipocytes in vitro (Zhang et al., 2007). Administration of capsaicin in 
high fat fed mice was shown to reduce adiposity by inhibiting adipogenesis. 
However, inhibition of adipogenesis in vitro can be highly nonspecific and the 
approach of inhibiting adipose development is unlikely to change energy balance 
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in vivo. Most likely, the difference in obesity observed in the study was due to 
reduced food intake caused by capsaicin administration. The other report using 
Trpv1-/- mice reached the opposite conclusion from the first report. Genetic loss 
of TRPV1 resulted in higher energy expenditure and less weight gain (Motter and 
Ahern, 2008). Moreover, the authors failed to detect TRPV1 expression in 
adipocytes and therefore suggested the effect was not cell-autonomous in 
adipocytes. Overall, based on these two conflicting reports, it is difficult to 
establish whether TRPV1 has a positive or negative role in obesity.  
TRPM8, another TRP channel that is activated by cold and menthol has recently 
been reported to control a thermogenic program in brown adipocytes. Treating 
high fat fed mice with menthol, a TRPM8 agonist, increased BAT-mediated 
thermogenesis and therefore reduced obesity and improved insulin resistance in 
these mice, suggesting a previously unrecognized role of TRPM8 in promoting 
BAT thermogenesis (Ma et al., 2012). 
 
 
 
 
 
 
 
 
Chapter 2: 
TRPV4 Regulates Oxidative Metabolism and Thermogenesis in 
Adipocytes 
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Introduction 
Obesity is fundamentally a result of an imbalance in energy intake and energy 
expenditure. Manipulating the components of the energy equation is a 
straightforward approach that could ultimately alter the progression of obesity 
and development of obesity-related metabolic consequences. Brown adipose 
tissue is a specialized organ that dissipates stored chemical energy into heat, a 
process called thermogenesis that significantly contributes to whole body energy 
expenditure in animals. However, in obesity, most of the excess adipose tissue is 
white adipose tissue, which has very little capacity for utilizing stored fat for heat 
(thermogenic capacity). Therefore, converting white into brown fat, or imparting 
brown fat-like thermogenic properties on white adipose tissue is an appealing 
approach to alter the energy imbalance that causes obesity. 
The functional conversion between white and brown adipocytes is known to 
happen under certain physiological conditions. For example, chronic cold 
exposure, beta-adrenergic agonism and TZD treatment, are all known to promote 
brown-fat like properties in white adipose tissue in animals models (Cousin et al., 
1992; Ghorbani and Himms-Hagen, 1997; Guerra et al., 1998; Himms-Hagen et 
al., 2000; Xue et al., 2005). Transcriptional control has been shown to be 
important in this conversion. Several transcription factors/ co-factors, such as 
PGC1α, PDRM16, FOXO1 and CEBP/b have been shown to play important roles 
(Kajimura et al., 2010). Ectopic expression of these transcription factors by viral 
vectors or transgenic approaches in white adipose tissue or cultured adipocytes 
27 
 
can activate the oxidative and thermogenic gene programs, and therefore alter 
energy metabolism.  
Among these factors, PGC1α appeared to be an appealing target. We 
hypothesized that increased PGC1α expression would likely alter the gene 
programs toward a more oxidative and thermogenic direction in white adipocytes, 
for the following reasons. First, the expression level of PGC1α was actively 
regulated under different physiological conditions. For example, cold exposure or 
cAMP stimulation significantly up-regulates PGC1α expression whereas high-fat 
diet and obesity effectively down-regulates it. Secondly, changes in PGC1α 
expression have been shown to have profound biological effects in the gene 
programs that are controlled by PGC1α in different systems (Lin et al., 2002; 
Puigserver et al., 1998; Tiraby et al., 2003). Lastly and importantly, as a co-
activator rather than an individual transcription factor or enzyme, PGC1α controls 
a whole set of genes that are important in oxidative metabolism and 
thermogenesis, such as enzymes in beta-oxidation, electron transport chains, 
mitochondrial biogenesis, uncoupling protein and ROS clearance (Spiegelman 
and Heinrich, 2004). Hence, it is believed that an increase in PGC1α would result 
in a “coordinated” increase in cellular energy metabolism. 
It is conceivable that increased expression of PGC1α would lead to increased 
mitochondrial content, elevated oxidative capacity, and promote thermogenesis 
in white adipocytes, which we here define as the “browning” of the white fat. 
However, viral or transgenic approaches are not a practical means of 
manipulating those pathways in humans for therapeutic purposes. While 
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chemical biology has been mainly considered as a tool for drug development in 
the pharmaceutical industry, recent advances in chemistry and high-throughput 
screening technologies have allowed academic laboratories to use this approach 
to look for small molecules that regulate important biological targets. It can be 
used to establish proof of concept of the “druggability” of targets and provide 
preliminary scaffolds which others can utilize for drug development.  
A similar screen for chemical inducers of PGC1α has been done in myotubes. 
After realizing that elevated PGC1α in muscle plays an anti-dystrophic and anti-
atrophic function, we previously screened for drugs and drug-like molecules that 
elevate PGC1α in primary murine muscle cells (Arany et al., 2008). Several 
inhibitors of microtubules and protein synthesis were identified as PGC1α 
inducers. This illustrated that screening for activators of PGC1α expression could 
identify compounds capable of increasing mitochondrial action. Conversely, 
when a screen for chemicals that could alter mitochondrial function was carried 
out, an overlapping set of regulators of PGC1α was uncovered (Wagner et al., 
2008). Unfortunately, none of these compounds had an activity/toxicity ratio that 
was favorable for animal or human studies.  
In this study, we have screened a chemical library for compounds that could 
increase PGC1α gene expression in adipocytes. We used a library of 3000 
compounds, most of which are either FDA-approved drugs or have known 
biological targets. This selection is critical as we not only are looking for drug-like 
small molecules that can be used to demonstrate the “druggability” of PGC1α, 
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but may also identify novel connections between known signaling pathways and 
the molecular control of PGC1α expression.  
We chose 3T3-F442A cell as our screening platform. 3T3-F442A is a clonal 
adipogenic cell line from immortalized Swiss 3T3 cell lines. They undergo 
spontaneous differentiation into adipocytes, and the process can be enhanced 
with insulin (Green and Kehinde, 1976). There are several reasons that 3T3-
F442A cells were used for the screen. First, 3T3-F442A cells are clonal, 
immortalized cells, which could give highest reproducibility with little variation 
between experiments. Second, they can differentiate into adipocytes with 
minimal external hormonal stimulation (insulin alone), which minimizes any 
possible drug-drug interaction in the compound treatment step in the screening 
and also makes the screen setup simple. Third, 3T3-F442A is the only adipocyte 
cell line that can form fat pats when they are injected into mice, indicating they 
are a very close alternative to in vivo systems (Mandrup et al., 1997). Last but 
most importantly, it is known that transcription factors that are important for the 
“browning” in vivo; can function normally in 3T3-F442A adipocytes in terms of 
regulating thermogenic gene expression and cellular physiology. On the other 
hand, many of those factors failed to regulate those pathways in 3T3-L1 cells, 
another popular model system for adipocyte biology (unpublished observation).  
 
 
 
30 
 
Results 
A Chemical Screen Identifies TRPVs as Negative Regulators of Pgc1α 
Expression 
We performed a quantitative PCR-based chemical screen to identify small 
molecules that can induce Pgc1α mRNA expression in white adipocytes. Fully 
differentiated 3T3-F442A adipocytes were treated with a chemical library of 3,000 
drugs and drug-like compounds for 20 hours; mRNA from treated cells was then 
harvested and analyzed by qPCR to quantify the expression of Pgc1α (Figure 
2.1). 33 primary candidates were identified from the screen, many of which 
overlapped with the results from the myotube Pgc1α screen, including 9 protein 
synthesis inhibitors and 5 mitochondrial respiration chain inhibitors. Of note, the 
screen also identified several ion channel inhibitors, protein modification 
inhibitors, and lipid derivatives.  
AM-251, a cannabinoid receptor 1 (CB1) antagonist was identified as one of the 
primary hits. It induced Pgc1α mRNA 10 fold at 20uM (Figure 2-2 A). AM-251 is a 
structural analogue of another well-known CB1 antagonist rimonabant (Lan et al., 
1999), an anti-obesity drug that was in clinical use in Europe but later was 
withdrawn due to psychiatric side effects. Although AM-251 is annotated as a 
CB1 antagonist, two other CB1 antagonists, SLV319 (Lange et al., 2004) and 
CAY10508 (Muccioli et al., 2006), failed to induce Pgc1α at any dose tested (0.2-
20uM) (Figure 2-2 A). Importantly, other molecular targets of AM251 or 
rimonabant have been reported when these compounds were used at 10uM or  
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above including TRPV1 (De Petrocellis et al., 2001; Zygmunt et al., 1999) . As 
shown in Figure 2-2 B, two TRPV1 antagonists, AMG9810 and BCTC, increased 
Pgc1α mRNA expression in 3T3-F442A adipocytes in a dose-dependent manner. 
Moreover, key transcriptional targets of PGC1α such as Cytochrome C (CytC) 
and Ucp1, were also increased at the mRNA level both basally and after cAMP-
stimulation (Figure 2-2 C).  
AMG9810 is known to antagonize TRPV1 but can also antagonize closely related 
TRPVs, such as TRPV2, TRPV3 and TRPV4, at the micromolar doses used here 
(Gavva et al., 2005). We therefore compared the mRNA expression of Trpv1, 
Trpv2, Trpv3 and Trpv4 in 3T3-F442A adipocytes. As shown in Figure 2-3 A, 
mRNAs encoding Trpv1, Trpv2 and Trpv4 were expressed in 3T3-F442A 
adipocytes, with Trpv4 being expressed at the highest level. To determine which 
of these channels were regulating Pgc1α expression, we used shRNA-mediated 
knock-down of each of the expressed TRPVs with lentiviral expression vectors. 
As shown in Figure 2-3 B, Trpv1, Trpv2 and Trpv4 mRNA were each significantly 
reduced by the corresponding shRNA expressed from lentiviral vectors, with no 
apparent cross-regulation. None of the shRNAs appeared to affect adipose 
differentiation per se, as indicated by the similar expression of the adipose-
selective gene aP2 (Figure 2-3 C). Pgc1α mRNA was strongly induced by the 
shRNA against TRPV4; shRNA against TRPV1 also had a small effect (Figure 2-
3 D). This functional data, along with the fact that the expression of Trpv4 mRNA 
was 10 times higher than that of Trpv1 in these cells, strongly suggested that  
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Figure 2-2. TRPV1 antagonists induce Pgc1α mRNA expression in adipocytes. 
QPCR analysis of Pgc1α mRNA in fully differentiated 3T3-F442A adipocytes 
after 24-hour treatment with indicated CB1 antagonists (A) or TRPV1 antagonists 
(B). All chemicals were used at three doses: 0.2, 2 and 20uM, except AM251 
(20uM). (C) QPCR analysis of Pgc1α, CytC and Ucp1 mRNA in adipocytes 
treated with 20uM AMG9810 or DMSO, at basal level or after Forskolin (10uM) 
stimulation. Data are presented as mean ± sem. Student’s t-test was used for 
single comparisons. * P<0.05, ** P<0.01, *** P<0.001, compared to control group.
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TRPV4 was the dominant TPRV family member regulating the induction of Pgc1α 
mRNA by the chemical inhibitors. 
TRPV4 is a Negative Regulator of Oxidative Metabolism, Thermogenic 
Pathway and Respiration in Adipocytes 
TRPV4 is a calcium permeable, non-selective ion channel that was first identified 
as an osmolality sensor (Liedtke et al., 2000; Strotmann et al., 2000).  Since then, 
many physical and chemical stimuli have been shown to activate TRPV4 (Nilius 
et al., 2004), including warmth (Guler et al., 2002; Watanabe et al., 2002), 
mechano-stimulation (Gao et al., 2003a), endocannabinoids (Watanabe et al., 
2003) and bisandrographolide A (BAA) (Smith et al., 2006). Adipose tissue was 
shown to have one of the highest levels of Trpv4 mRNA expression (Liedtke et 
al., 2000). We also found that in general Trpv4 expression was higher in white 
adipose tissues (including epididymal, inguinal and retroperitoneal fat) than in 
brown adipose tissue (Figure 2-4 A).  
We used retroviral vectors expressing an shRNA against TRPV4 or GFP to make 
stable cells with altered TRPV4 expression for biochemical and bioenergetic 
analyses. Again, the ectopic retroviral shRNA did not appear to effect adipocyte 
differentiation per se (Figure 2-4 D). We first examined if there were functional 
TRPV4 channels present in 3T3-F442A adipocytes. TRPV4 protein was detected 
at the predicted molecular weight, by western blot (Figure 2-4 B). In addition, we 
used intracellular calcium measurement as a functional assay to test for TRPV4 
conductivity.  
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Figure 2-3. Identification of TRPV4 as the major TRPV family member in 
adipocytes.  (A) Normalized mRNA expression of Trpv1, Trpv2, Trpv3 and Trpv4 
in 3T3-F442A adipocytes, by QPCR. (B) Trpv1, Trpv2 and Trpv4 mRNA levels in 
adipocytes infected with scrambled (SCR), shTRPV1, shTRPV2 or shTRPV4 
lentivirus. aP2 (C) and Pgc1α (D) mRNA levels in these adipocytes. Data are 
presented as mean ± sem. Student’s t-test was used for single comparisons. * 
P<0.05, ** P<0.01, *** P<0.001, compared to control group.  
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GSK1016790A, a potent and selective TRPV4 agonist (Thorneloe et al., 2008; 
Willette et al., 2008), induced a robust and rapid increase in intracellular calcium 
in adipocytes at 100nM. This calcium increases by GSK1016790A treatment was 
highly dependent on the presence of TRPV4, as it was largely abolished by the 
shRNA against TRPV4 (Figure 2-4 C). 
Pgc1α mRNA expression was 3-10 times higher in adipocytes expressing shRNA 
against TRPV4 with this retroviral system, compared to controls (Figure 2-5 A). 
At the basal state, TRPV4 knockdown adipocytes did not have significant higher 
UCP1 mRNA expression. β-adrenergic signaling is important for the induction of 
PGC1α and its target genes in thermogenesis. When cells were exposed to 
norepinephrine, mRNA expression of Pgc1α and its thermogenic target Ucp1 
was robustly increased (4-7 fold) in the TRPV4 knock-down cells compared to 
controls (Figure 2-5 A). PGC1α is known to drive the expression of many genes 
involved in mitochondrial oxidative phosphorylation, including cytochrome c 
(CytC), and the cytochrome C oxidative (COX) subunits (CoxIII, Cox4il, Cox5b, 
Cox7a and Cox8b) which are important for the electron transport chain on the 
mitochondrial inner membrane. We observed higher mRNA expression of these 
genes (1.5-2fold) in TRPV4-knockdown adipocytes compared to controls (Figure 
2-5 B). In addition, the TRPV4-knockdown adipocytes showed significantly higher 
expression of proteins present in all five OXPHOS complexes (Figure 2-5 C). 
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Figure 2-4. Functional expression of TRPV4 in adipocyte and adipose tissue. (A) 
QPCR analysis of TRPV4 mRNA in interscapular brown fat (BAT), inguinal (ING), 
axillary (AXL), epididymal (EPI) and retroperitoneal (RP) fat. (B) TRPV4 protein 
in 3T3-F442A adipocytes were infected with retrovirus expressing shTRPV4 or 
shGFP.(C) Oil-Red-O staining (red) for lipid accumulation. mRNA levels of 
general adipocyte markers (aP2, Adiponectin and PPARγ) were also 
determined.(D) Intracellular calcium measurement, the calcium level was 
presented as ratio of 340nm/380nm emission from Furo-2.  
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The increased expression of Pgc1α, Ucp1 and other mitochondrial genes 
suggested that TRPV4 inhibition caused white adipocytes to develop brown fat-
like characteristics, which we termed “browning” here. To determine the impact of 
this browning gene program on cellular physiology, oxygen consumption was 
measured in adipocytes in a closed chamber with an oxygen sensitive Clark 
electrode at the bottom. As shown in Figure 2-5 D, TRPV4 knockdown has 
significant effects on the basal, uncoupled and maximal cellular respiration rate. 
Adipocytes with reduced TRPV4 showed a 40% increase in basal respiration, a 
30% increase in uncoupled and a 30% increase in FCCP-stimulated maximal 
respiration, relative to controls, indicating the elevated mitochondrial oxidative 
gene program was associated with increased cellular respiration in these cells. 
We next examined whether chemical activation of TRPV4 would have the 
opposite impact on the same pathways. The TRPV4 agonist GSK1016790A was 
added to mature 3T3-F442A adipocytes for 48 hours. While there was no 
difference in adipocyte differentiation, as assessed by aP2 gene expression, 
GSK1016790A repressed the expression of mRNAs encoding Pgc1α, Ucp1 and 
Cox8b in a dose-dependent manner (Figure 2-5 E). Taken together, these data 
strongly suggest that TRPV4 functions as a negative regulator of PGC1α and 
oxidative metabolism in white adipocytes. 
TRPV4-deficient Mice Have Altered Expression of Thermogenic Genes in 
Adipose Tissue 
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Figure 2-5. TRPV4 negatively regulates oxidative metabolism and respiration in 
adipocytes. 3T3-F442A adipocytes were infected with retrovirus expressing 
shTRPV4 or shGFP. (A) Pgc1α and Ucp1 mRNA expression, with or without 
100nM norepinephrine stimulation. (B) mRNA expression and (C) protein 
expression of mitochondrial components. (D) Basal, uncoupled and maximum 
oxygen consumption rates. (E) mRNA expression of aP2, Pgc1a, Ucp1 and 
Cox8b in 3T3-F442A adipocytes, after 48 hours treatment of GSK1016790A at 
indicated doses. Data are presented as mean ± sem. Student’s t-test was used 
for single comparisons. * P<0.05, ** P<0.01, *** P<0.001, compared to control 
group. 
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To investigate the function of TRPV4 in regulating oxidative and thermogenic 
programs in adipose tissues in vivo, we studied mice with a genetic deletion of 
Trpv4. These mice are grossly similar to wild-type animals in morphology, 
behavior and breeding (Liedtke and Friedman, 2003). On a chow diet, their body 
weight is indistinguishable from WT littermate controls (Figure 2-6 A).  In light of 
the effect of TRPV4 on oxidative metabolism in white adipocytes, we examined 
gene expression in white adipose tissues from Trpv4-/- and WT control mice. 
Subcutaneous adipose tissue has been shown to have a greater thermogenic 
capacity than other white adipose tissues (Barbatelli et al., 2010) and can 
significantly contribute to whole body energy homeostasis (Seale et al., 2011). 
Strikingly, subcutaneous fat from Trpv4-/- mice expressed 30 fold higher Ucp1 
mRNA and more UCP1 protein compared to controls (Figure 2-7 A, G).  A trend 
towards increased Pgc1α (p=0.08) and significantly higher Pgc1β were also 
observed. These mice also have elevated mRNA levels for many genes, 
including mitochondrial components known to be enriched in BAT, such as Cidea, 
Cox4il, and Cox8b (Figure 2-7 A).  
In general, visceral (epididymal) adipose tissues have a low thermogenic 
capacity and expresses very little Ucp1 and Cidea (data not shown). Nonetheless, 
mRNA levels for some BAT enriched genes, such as β3Adr, Pgc1β, CytC, Cox4il 
and Cox5a, were significantly higher in epididymal fat from the Trpv4 -/- mice 
compared to controls (Figure 2-7 D). 
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Figure 2-6. Trpv4-/- mice gain less body weight on high fat diet.  Body weights of 
male WT and TRPV4-/- mice on chow (A) and HFD (B) over 16 weeks. Data are 
presented as mean ± sem. (n=9-13 in each group) Comparisons were analyzed 
by student’s t-test. * P<0.05 
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Exposure of mice to a high fat diet (HFD) induces obesity and eventually leads to 
insulin resistance in fed animals. To further understand how TRPV4 deficiency 
affects gene expression under this metabolic stress, we challenged these mice 
with a HFD that contains 60% calorie from animal fat. There was no significant 
body weight difference between the Trpv4-/- and control mice until the animals 
were on the HFD for 9 weeks (Figure 2-6 B).  
The adipose tissues were first examined at 8 weeks of HFD, before the body 
weight of Trpv4-/- mice diverged from controls. Although the HFD tended to blunt 
the difference in thermogenic gene expression seen in chow-fed animals, 
subcutaneous fat from the Trpv4-/- animals nevertheless expressed 3 times 
higher levels of Ucp1 mRNA (Figure 2-7 B) and more UCP1 protein (Figure 2-7 
G) than controls. A trend toward higher expression of BAT enriched thermogenic 
genes such as β3Adr, Pgc1α and Cidea was also observed in the Trpv4-/- 
subcutaneous fat. Histological analysis also showed that mutant mice have 
smaller fat cells and more UCP1-positive adipocytes in this depot compared to 
controls (Figure 2-7 H). Despite the low absolute level, significantly higher β3Adr 
and Cox8b mRNA expression was also observed in the epididymal fat from 
Trpv4-/- mice (Figure 2-7 E).  
As the exposure to the HFD extended to 16 weeks, many BAT enriched and 
thermogenic genes were no longer different between the Trpv4-/- and control 
mice, such as Ucp1. However, the Trpv4-/- mice still had elevated expression of  
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Figure 2-7.  Altered thermogenic programs in Trpv4-/- adipose tissue. QPCR 
analysis of mRNA expression of thermogenic and brown fat-selective genes in 
subcutaneous (A-C) and epididymal (D-F) adipose tissues from Trpv4-/- and WT 
mice, with exposure to chow (A, D), 8-week high fat diet (B,E) or 16-week high 
fat diet (C, F). (D) Western blot analysis of UCP1 protein, from chow and 8-week 
HFD mice. (E) Representative images from immunohistochemistry for UCP1 
(brown stain) protein in subcutaneous fat from WT and Trpv4-/- mice after 8 
weeks of HFD. UCP1-expressing adipocytes are indicated by arrows Data are 
presented as mean ± sem. (n=9-13 in each group) Student’s t-test was used for 
single comparisons. * P<0.05, ** P<0.01, *** P<0.001, compared to control group. 
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mRNAs encoding β3adr and Pgc1α in both the inguinal and epididymal fat 
depots (Figure2-7 C, F). Overall, in both lean (chow-fed) and obese animals, 
Trpv4-/- adipose tissues have more active oxidative and thermogenesis gene 
expression, which is consistent with our finding in cultured adipocytes in vitro. 
Increased Energy Expenditure Protects TRPV4 Deficient Mice from Diet-
induced Obesity 
Based on the gene expression changes observed in Trpv4-/- mice, we were 
interested if the TRPV4 mutation would have a protective role in diet-induced 
obesity. The body weight curves showed that the TRPV4 mutant mice began to 
gain significantly less weight after 9 weeks on the HFD, compared to their age- 
and sex- matched WT littermates (Figure 2-6 B). To determine the exact 
difference in the components of the weight difference, we first did body 
composition analysis in Trpv4-/- and WT control mice, which showed that the 
mutant mice had gained less fat, resulting in a higher lean/fat mass ratio 
compared to WT controls (Figure 2-8 A).  
We then performed careful metabolic analysis by indirect calorimetric to 
determine the cause of the difference in weight gain on high fat diet seen in WT 
and Trpv4-/- mice. Energy expenditure in these mice was measured via oxygen 
consumption after 8-week of HFD, right before the body weight of mutants 
diverged from controls. We observed higher oxygen consumption during both 
day and night time in the Trpv4-/- mice, compared to WT controls (Figure 2-8 B), 
a result consistent with the elevated thermogenic program in white adipose tissue.  
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Figure 2-8. Increased energy expenditure protects TRPV4 deficient mice from 
diet-induced obesity. Male WT and Trpv4-/- mice on chow and HFD over 16 
weeks. (A) MRI analysis of body composition (fat, lean and water mass) after 12 
weeks HFD. energy expenditure (as oxygen consumption rate, B and CO2 
production rate, C) , 24-hour food intake (D) and physical activity (E)  was 
measured in individually housed WT and Trpv4-/- mice after 8 weeks HFD. Data 
are presented as mean ± sem. (n=9-13 in each group) Two-way ANOVA was 
used for panel B, C and E; others single comparisons were analyzed by student’s 
t-test. * P<0.05, ** P<0.01, *** P<0.001, n.s. not significant.  
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A higher CO2 production was observed in Trpv4-/- mice (Figure 2-8 C). 
Importantly, there was no significant difference in food intake (Figure 2-8 D) or 
physical activity (Figure 2-8 E) between the two genotypes, indicating the energy 
intake or the expenditure by physical movement was not altered in the Trpv4-/- 
mice. Taken together, these data strongly suggest that the reduced weight gain 
upon HFD in Trpv4-/- mice was due to, at least in part, an increased energy 
expenditure associated with increased thermogenesis in their white adipose 
tissue. 
A Cell-autonomous Up-regulation of Thermogenic Program in Trpv4-/- 
Adipocytes 
We observed the expected physiological changes in the Trpv4-/- mice according 
to their adipose gene expression changes. However, because the Trpv4-/- mice 
we studied have a whole body TRPV4 deficiency, it is important to know whether 
any other metabolically active tissues also contribute to the whole body 
phenotype; and if so, how much of the whole body phenotype was due to the 
“browning” of the white adipose tissue and how much was coming from other 
tissues. 
We first examined the classic brown adipose tissue, the interscapular BAT, in 
Trpv4-/- and WT control mice. Under both chow (Figure 2-9 A) and HFD 
conditions (Figure 2-9 B), no significant difference in mRNA expression of 
thermogenic or oxidative genes was detected between the mutant and WT mice.  
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Figure 2-9. Trpv4-/- mice have minimal change in thermogenic and oxidative 
pathways in interscapular brown fat and skeletal muscle. The expression of 
thermogenic and brown fat specific genes were examined by QPCR in 
interscapular brown fat from Trpv4-/- and WT mice, under chow (A) or 16-week 
high fat diet (B).Expression of genes involved in oxidative metabolism were 
examined from quadriceps muscle from Trpv4-/- and WT mice, under chow (C) 
or 16-week high fat diet (D) conditions. Data are presented as mean ± sem. 
Student’s t-test was used for single comparisons. * P<0.05, ** P<0.01, *** 
P<0.001, n.s. not significant, compared to control group.  
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There was a report that TRPV4 deficiency caused a higher oxidative capacity in 
skeletal muscle (Kusudo et al., 2011). However, in that report, the authors only 
examined the soleus muscle in mice. More importantly, they only assessed the 
oxidative gene expression in the soleus muscle after a significant difference in 
body weight had occurred between knockout and WT mice. We examined 
quadriceps gene expression of Trpv4-/- and WT mice under chow and HFD. 
While myogenin expression were up-regulated in the mutant mice under HFD as 
reported (Figure 2-9 D), there was no difference seen in myogenin as well as the 
oxidative/mitochondrial genes, such as carnitine palmitoyltransferase I- beta 
(Cpt1b), citrate synthase (Cs), cytochrome C (CytC) and Isocitrate 
dehydrogenase (Idh3a),  when mice were on chow diet and lean (Figure 2-9 C). 
This suggested that the difference observed in the other report was likely a 
secondary effect of obesity. 
We examined two metabolically active organs, BAT and skeletal muscle. Neither 
of them seemed to have significant gene expression changes associated with 
TRPV4 deficiency, whereas strong effects were seen in the white adipose tissue. 
However, it is still not clear whether the difference in white adipose tissue was 
due to secondary effects from other tissues that we did not look at, such as brain, 
sensory neurons, etc. Therefore we asked if the phenotype observed in vivo was 
associated with any cell-autonomous alterations in adipocyte cultures derived 
from these mice. To test this, stromal-vascular cells from the adipose tissue of 
young, lean Trpv4 -/- and WT mice were isolated and stimulated to differentiate  
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Figure 2-10. TRPV4 controls adipocyte thermogenic gene program in a cell-
autonomous manner. (A) Mitochondrial and brown fat selective gene expression 
in in vitro differentiated Trpv4-/- and WT primary adipocytes at the basal level. (B) 
Pgc1α and Ucp1 mRNA in these adipocytes at basal, and after stimulation with 
10nM or 100nM norepinephrine for 4 hours. Data are presented as mean ± sem. 
Student’s t-test was used for single comparisons. * P<0.05, ** P<0.01, *** 
P<0.001, n.s. not significant, compared to control group. 
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into adipocytes in vitro. After 8 days, greater than 90% of the cells were fully 
differentiated. Compared to those from WT controls, unstimulated adipocytes 
from Trpv4 -/- animals showed elevated mRNA expression for Pgc1α and Ucp1, 
β3adr, Cox7a, Cox8b, CytC and Cidea (Figure 2-10 A). Importantly, when 
stimulated with 10nM or 100nM norepinephrine, the Trpv4-/- adipocytes had 
much greater responses in terms of Pgc1α and Ucp1 expression (Figure 2-10 B). 
Taken together, these data indicate that TRPV4 controls the oxidative and 
thermogenic programs in a cell autonomous manner. 
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Discussion 
In this chapter, we identified a novel connection between the TRPV channels and 
the regulation of PGC1α expression, by a high-throughput, quantitative PCR 
based chemical screen. The initial candidate from the primary screen turned out 
to be an off-target effect of a well-characterized drug-like compound. We 
identified the actual target of this compound through both pharmacological and 
genetic approaches. We demonstrated that functional TRPV4 channel was 
expressed in cultured adipocytes in vitro and in adipose tissues, particularly white 
adipose tissue in vivo. Genetic or pharmacological manipulation of TRPV4 clearly 
demonstrated that TRPV4 was a negative regulator of PGC1α and the 
downstream gene programs controlled by PGC1α, namely the mitochondrial 
oxidative program and thermogenesis. A mouse model with a genetic TRPV4 
deficiency showed consistent phenotypes in terms of gene expression and 
physiology, according to the functions of TRPV4 identified in vitro.  
The High Throughput Screen Platform for Mature Adipocytes 
We modified and optimized the previously used QPCR-based chemical screen 
platform for adipocytes. It is of particular interest to study mature adipocytes, 
especially given the relevance in obesity and metabolic diseases. However, one 
technical challenge of performing high throughput screens is that there is a large 
amount of lipid in fully differentiated adipocytes that often interferes with the 
micropipettes handling liquids throughout the steps. One simple solution is to 
lower the cell density in such assays. However, cell confluence is usually 
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required for good in vitro differentiation in fat cell lines or primary adipocytes. In 
our optimized system, we balanced the cellular density and lipid content by 
trypinizing and re-plating “half-differentiated” adipocytes into high throughput 
format (384 wells) two days after the initiation of differentiation. This method 
resulted in a good yields and highly consistent performance. We have used this 
platform for screening for inducers of PGC1α mRNA expression, but it is 
conceivable that it can be easily modified for other expression based or image 
based screening in mature adipocytes. 
TRPVs and Adipocyte Biology 
One advantage of using a library consisting of compounds mostly with known 
bioactivity is to identify novel connections between a well characterized pathway 
and the screening target. TRPVs are a well-characterized ion channel family, 
particularly in terms of their channel electrophysiology and biophysical properties. 
Most detailed information about the TRPV family came from the study of TRPV1, 
the capsaicin and putative heat receptor in sensory neurons. Extensive and 
intensive pharmacology has been done on the TRPV1 channel, with a goal of 
developing new classes of peripheral acting analgesics. Many small molecules 
(both agonist and antagonist) targeting TRPV1 or other TRPVs have been 
developed and some of them have been used in clinical trials (Wong and Gavva, 
2009).  
The sophisticated pharmacology of TRPVs makes the identification of the new, 
cell-autonomous functions of TRPVs in regulating adipocyte physiology 
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particularly interesting. There have been reports suggesting TRPVs might play 
roles in different aspects of adipose biology. TRPV1 has been reported to inhibit 
adipogenesis in vitro and in vivo. Paradoxically, both TRPV1 deficiency and 
activation were suggested to protect animals against diet induced obesity, 
although the mechanism and/or responsible cell/tissue types have not been well 
understood (Motter and Ahern, 2008; Zhang et al., 2007). Recently, TRPM8 also 
has been suggested to regulate thermogenesis in classical brown adipose tissue, 
but it is unclear if the effect was cell-autonomous or through other CNS mediated 
mechanisms (Ma et al., 2012). Nevertheless, this study first demonstrated that a 
chemically trackable TRPV channel can regulate energy metabolism in 
adipocytes in a cell-autonomous manner, both in cultured cells and in whole 
animals. More importantly, this regulation appeared to play an important role in 
the development of obesity and pathogenesis of metabolic disorders. This finding 
illustrated that chemical biology approaches are not only extremely powerful in 
identifying novel pathway, but could also bring the finding quickly to 
pharmacology and potential therapeutic applications. 
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Materials and Methods 
Materials 
Antibody sources are as follows: anti-UCP1 and anti-OXPHOS (Abcam), anti-
TRPV4 (Alomone). Forskolin, norepinephrine, GSK1016790A, AMG9810, AM251, 
insulin, dexamethasone, isobutylmethylxanthine and puromycin were from Sigma. 
BCTC was from Tocris. SLV319, CAY10508 and Rosiglitazone were from 
Cayman Chemica.. shRNA constructs were in pLKO vectors (for lentivirus) or 
pMKO vectors (for retrovirus).  
Animals 
All animal experiments were performed according to procedures approved by the 
Institutional Animal Care and Use Committee of Dana-Farber Cancer Institute. 
Mice were either maintained on a standard rodent chow or a 60% high-fat diet 
(Research Diets) with 12-hour light and dark cycles. Trpv4-/- mice were provided 
by Dr. Liedtke (Liedtke and Friedman, 2003) and back-crossed to C57BL/6J 
(Jackson Lab) for 10 generations before all studies. Each study group contains 9-
13 animals of each genotype. 
Chemical Screen 
Briefly, after two days of differentiation, 3T3-F442A adipocytes were trypsinized 
and split into 384 well plates (3000 cell/well). At day 6, adipocytes were treated 
with a chemical library (Broad Institute) in 384-well plates for 20 hours at ~20uM. 
mRNA was harvested using the TurboCapture kit (Qiagen), reverse transcribed 
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to cDNA, and quantified by qPCR with Sybr-Green (ABI). All values were 
normalized to vehicle (DMSO) treated wells. 
Cell Culture 
For virus production, 293T (for lentivirus) or ϕnx cells (retrovirus) were 
transfected with Fugene 6 (Roche) with viral vectors. Viral supernatant was 
harvested 48 hours late. 3T3-F442A pre-adipocytes were infected for 4 hour 
(lenti) or overnight (retro), followed by puromycin selection (2ug/ml). 3T3-F442A 
adipocyte differentiation was induced in cultures by treating confluent cells with 
850 nM insulin for 8-10 days. To stimulate thermogenesis, cells were incubated 
with forskolin (10uM) or norepinephrine (10nM or 100nM) for 4 hours. For 
primary adipocytes, SVF from inguinal fat depots of 5-week-old male mice were 
prepared and differentiated for 8 days as previously described (Kajimura et al., 
2009). Rosiglitazone (1uM) was used for the first two days of differentiation. n=3 
or 4 in each group for all cell culture experiments. 
QPCR and Western Blotting 
Total RNA from cultured cells or tissues was isolated using the TRIzol method 
(Invitrogen) combined with Qiagen RNAEasy mini columns according to the 
manufacturer’s instruction. For qPCR analysis, RNA was reverse transcribed 
using the ABI high capacity cDNA synthesis kit and used in quantitative PCR 
reactions containing SYBR-green fluorescent dye (ABI). Relative expression of 
mRNAs was determined after normalization with TBP levels using the ∆∆Ct 
method. For TRPV1, TRPV2 and TRPV4 expression, the standard curve method 
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was used to quantify the absolute copy numbers. The standard curves were 
generated with pMSCV plasmids containing TRPV1, TRPV2 and TRPV4 cDNA. 
For Western blot analysis, cells or tissues were lysed in RIPA buffer (0.5% NP-40, 
0.1%sodium deoxycholate, 150 mM NaCl, 50 mM Tris-Cl, pH 7.5). Lysates were 
resolved by SDS-PAGE, transferred to PVDF membrane (Millipore), and probed 
with the indicated antibodies.  
Calcium Imaging 
At day 6 of differentiated, 3T3-F442A adipocytes were trypsinized and 
transferred to coverslip coated with Cell-Tak solution (BD Biosciences). Cells 
were loaded with 10 uM Fura-2AM (Invitrogen) for 20 min at 37oC and 
then washed twice in standard Tyrodes Solution (in mM): 135 NaCl, 4 KCl, 10 
glucose, 10 HEPES, 1.2 CaCl2, 1 MgCl2, pH 7.40 at room temperature. 
Fluorescence images were obtained (at 510 nm) using an Olympus IX81 inverted 
microscope with a 20X objective (Olympus) and a CCD camera (Hamamatsu, 
Model# C4742-80-12AG) upon sequential excitation with 340 nm followed by 380 
nm light. After establishing a baseline 340/380 ratio, a selective TRPV4 agonist, 
GSK101 (100nM) was perfused onto the cells. 
Oxygen consumption assays  
3T3-F442A adipocytes expression control shGFP retrovirus or sh-TRPV4 were 
induced to undergo adipogenesis. At day 8 of differentiation, oxygen 
consumption was measured in fat cells using a strathkelvin Clark-type electrode. 
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1 μM oligomycin (Sigma-Aldrich) or 5uM FCCP (Sigma-Aldrich) was added to 
block state III respiration and induce uncoupling, respectively. 
Metabolic Study 
Body weight was measured on a weekly basis for high-fat feeding experiments. 
Fat and fat-free mass was measured by MRI. Whole-body energy metabolism 
was evaluated using a Comprehensive Lab Animal Monitoring System (CLAMS, 
Columbia Instruments). Mice were acclimated in the metabolic chambers for 2 
days before the starting the experiment to minimize stress from the housing 
change. CO2 and O2 levels were collected every 32 minutes for each mouse 
over a period of 3 days. Movement and food intake are measured more 
frequently at regular intervals. 
Histological analysis 
Tissues were dissected and fixed in 4% paraformaldehyde overnight and rinsed 
with phosphate-buffered saline before embedding in paraffin. For Ucp1 
immunohistochemistry, paraffin embedded sections were incubated with anti-
Ucp1 (Abcam), followed by detection using the ABC Vectastain-Elite kit (Vector 
Labs) according to the manufacturer’s instructions. 
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Introduction 
To understand the function of TRPV4 in adipocytes more fully, microarray 
analysis of global gene expression was performed with mRNA from 3T3-F442A 
adipocytes expressing shRNAs against TRPV4 or GFP. As expected, many 
genes whose expression was strongly increased were involved in brown 
adipocyte function and oxidative metabolism (Table 1). For example, acetyl-
coenzyme acyltransferase 1B, an enzyme mediating the last step of fatty acid β-
oxidation, was expressed 5 fold higher in TRPV4-knockdown adipocytes 
compared to controls. Similarly, mRNAs encoding the β-3 and β-1 adrenergic 
receptors, key receptors for catecholamines that control brown adipocyte function, 
were increased more than 3 fold. Pgc1α was also one of the most highly 
regulated genes on these arrays.  
Strikingly, many genes whose expression was decreased by TRPV4 knockdown 
were chemokines/cytokines or genes related to pro-inflammatory pathways 
(Table 1). For example, in the array the chemokine Ccl7 (Mcp3) mRNA was 
decreased by more than 85% in TRPV4 knockdown adipocytes. Expression of 
mRNA encoding Saa3, a pro-inflammatory amyloid protein secreted from 
adipose tissue, was reduced by 98%. 
This unexpected finding of TRPV4’s role in pro-inflammatory gene expression is 
particularly interesting, because chronic, low-grade inflammation in adipose 
tissue has been shown to be a hallmark of obesity and thought to be a major  
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Table 1. Genes regulated by TRPV4-knockdown in 3T3-F442A adipocytes 
Up-regulated Genes Change Down-regulated Genes Change 
similar to hepatocellular carcinoma-
associated gene TD26 18.54 serum amyloid A 3 -49.82 
thyroid hormone responsive SPOT14 
homolog (Rattus) 13.34 interferon-induced protein 44 -45.15 
gastrin releasing peptide receptor 7.46 chemokine (C-X-C motif) ligand 10 -25.11 
carbonic anhydrase 9 6.66 2'-5' oligoadenylate synthetase-like 2 -17.5 
sulfotransferase family 1A, phenol-preferring, 
member 1 5.42 lipocalin 2 -17.44 
RAR-related orphan receptor gamma 5.07 interferon activated gene 203 -11.88 
aldehyde dehydrogenase family 1, subfamily 
A1 4.99 
interferon-induced protein with 
tetratricopeptide repeats 1 -11.42 
phosphorylase kinase gamma 1 4.99 lipopolysaccharide binding protein -11.32 
acetyl-Coenzyme A acyltransferase 1B 4.9 2'-5' oligoadenylate synthetase 1A -9.84 
proteinase 3 4.82 interleukin 6 -9.35 
mannan-binding lectin serine peptidase 1 4.79 toll-like receptor 2 -9.26 
thyroid hormone responsive SPOT14 
homolog (Rattus) 4.79 chemokine (C-X-C motif) ligand 5 -8.47 
Rho GTPase activating protein 6 4.77 secreted frizzled-related protein 2 -7.48 
Inhibitor of DNA binding 4 4.68 
phosphoenolpyruvate carboxykinase 1, 
cytosolic -7.28 
growth hormone releasing hormone 4.53 inhibin beta-A -6.98 
selenium binding protein 1 4.47 complement factor B -6.86 
selenium binding protein 1 4.37 receptor transporter protein 4 -6.83 
adrenergic receptor, beta 1 4.33 chemokine (C-C motif) ligand 7 -6.63 
hippocalcin 4.22 insulin-like growth factor binding protein 3 -6.57 
complement factor D (adipsin) 4.17 STEAP family member 4 -6.43 
Mannan-binding lectin serine peptidase 1 4.11 WNT1 inducible signaling pathway protein 1 -6.41 
phosphorylase kinase gamma 1 3.99 chemokine (C-X-C motif) ligand 1 -6.32 
inhibitor of DNA binding 4 3.88 interferon activated gene 203 -6.23 
WNK lysine deficient protein kinase 4 3.84 
cytochrome P450, family 7, subfamily b, 
polypeptide 1 -6.18 
inhibitor of DNA binding 4 3.78 calpain 6 -6.13 
cytochrome c oxidase, subunit VIIIb 3.77 lumican -6.1 
resistin 3.73 solute carrier family 15, member 3 -6.06 
epoxide hydrolase 2, cytoplasmic 3.71 runt related transcription factor 1 -5.97 
inhibitor of DNA binding 4 3.64 runt related transcription factor 1 -5.91 
adrenergic receptor, beta 3 3.61 interleukin 1 receptor-like 1 -5.83 
apoptosis-associated tyrosine kinase 3.6 interferon, alpha-inducible protein 27 -5.74 
adrenergic receptor, beta 3 3.57 
component of Sp100-rs /// similar to 
component of Sp100-rs -5.44 
peroxisome proliferative activated receptor, 
gamma, coactivator 1 alpha 3.54 ribonuclease, RNase A family 4 -5.33 
gastrin releasing peptide receptor 3.49 interferon inducible GTPase 1 -5.29 
Peroxisome proliferative activated receptor, 
gamma, coactivator 1 alpha 3.39 P lysozyme structural -5.26 
 
Table 1.Positive fold change means higher expression in adipocytes with shRNA 
against TRPV4 compared to controls (shGFP). Negative value means reduced 
expression in these cells. Values in the table represented means from two 
samples in each group.  
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cause of insulin resistance associated with obesity (Gregor and Hotamisligil, 
2011). The initial discovery of this connection between chronic inflammation and 
insulin resistance was made more than 20 years ago. Since then, numerous 
studies have demonstrated that this inflammation was critical for the 
development of insulin resistance associated with obesity.  
The broad and substantial reduction of the chemotactic gene program in TRPV4 
knockdown adipocytes, rather than changes in individual genes, indicated that 
TRPV4 might function as an unexpected, yet very important upstream controller 
of this program. If true, manipulating TRPV4 would likely have profound effects in 
the expression and secretion of chemokines, and would therefore affect the 
recruitment of immune cells, with attendant metabolic consequences. 
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Results 
TRPV4 Positively Controls a Pro-inflammatory Gene Program  
Based on the microarray results, we used qPCR to further analyze the 
expression of 22 genes that are either highly regulated by TRPV4 (from the array) 
or are known from published literature to be important in adipose inflammation. 
Importantly, experimental reduction of TRPV4 expression had a profound 
inhibitory effect on a whole array of chemokines, such as Ccl2 (Mcp1), Ccl3 
(Mip1α), Ccl5 (Rantes), Ccl7 (Mcp3), Cxcl1 (KC), Ccl8, Cxcl5 and Cxcl10 and 
cytokines such as Il6, Saa3 and Thrombospondin (Figure 3-1 A). A similar effect 
was observed on the expression of other genes important for inflammatory 
processes, such as Tlr2, Timp1, Socs3, Socs5, Mmp2, Fas and Vcam (Figure 3-
1 B).  
Conversely, mRNA expression of Mip1α, Cxcl1, Il6, Timp1 and Tlr2, can be 
induced by treating adipocytes with the TRPV4 agonist (Figure 3-2 A). This effect 
is specific and dependent on TRPV4, as shRNA against TRPV4 fully abolished 
the induction by the agonist (Figure 3-2 A). 
To determine if these effects on gene expression resulted in alterations in 
chemokine secretion from adipocytes, we measured levels of secreted MCP1, 
MIP1α, CXCL1 and RANTES in culture medium by ELISA. Similar to what we 
observed at the mRNA level, the concentrations of MCP1, CXCL1 and RANTES 
were each reduced by more than 85% in the culture medium from the TRPV4 
knockdown adipocytes, compared to controls (Figure 3-2 B). The TRPV4 agonist  
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Figure 3-1. Loss of TRPV4 reduces pro-inflammatory gene expression in 
adipocytes. QPCR analysis of mRNA encoding chemokines/cytokines (A) and 
other genes involved in inflammatory pathways (B) in 3T3-F442A adipocytes with 
retrovirus expressing either shTRPV4 or shGFP (control).  
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induced MIP1α protein by 76 fold. Again, this induction was fully abolished by 
knocking down TRPV4 (Figure 3-2 B). These data indicate a very powerful role 
for TRPV4 in the regulation of a pro-inflammatory pathway in adipocytes. 
TRPV4 Deficiency Results in Reduced Pro-inflammatory Gene Expression 
in vivo 
We studied Trpv4-/- mice as described in Chapter 1, to examine the in vivo 
function of TRPV4 on the pro-inflammatory program. We measured the 
expression of pro-inflammatory genes, especially chemokines, identified from the 
analysis of TRPV4 knockdown 3T3-F442A adipocytes. These included Mcp1, 
Mip1α, Mcp3, Rantes and Vcam. These genes were expressed at very low levels 
in the adipose tissues of lean animals, and no significant differences were 
observed in either subcutaneous or epididymal adipose tissues between the 
mutants and controls on a chow diet (Figure 3-3 A, B). 
Exposure of wild type mice to a high fat diet (HFD) effectively induces obesity 
and provokes adipose inflammation, eventually contributing to insulin resistance. 
To further understand how TRPV4 deficiency affects adipose inflammation under 
this metabolic stress, we challenged Trpv4-/- mice and wild type controls with a 
60% high fat diet.  
Being aware that Trpv4-/- mice would gain less weight than WT controls, we 
wanted to eliminate the possible confounding effects from the body weight 
difference. Therefore, adipose tissues were first examined at 8 weeks of HFD, 
before the body weight of Trpv4-/- mice diverged from controls. We first looked at  
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Figure 3-2. Activation of TRPV4 induces pro-inflammatory gene expression and 
protein secretion. (A) mRNA expression of Mcp1, Mip1α, Rantes, Mcp3, Il6, 
Cxcl1, Timp1 and Tlr2 in 3T3-F442A adipocytes with shTRPV4 or shGFP, with or 
without 48 hours agonist treatment . (B) Protein concentrations of MCP1, MIP1α, 
CXCL1 and RANTES in culture medium from cell in (A) were determined by 
ELISA. Data are presented as mean ± sem. Student’s t-test was used for single 
comparisons. * P<0.05, ** P<0.01, *** P<0.001, compared to control group.
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visceral fat (epididymal fat) as this depot has more inflammation and is the 
primary source of inflammatory cytokine/adipokines.  As expected, eight weeks 
of HFD was enough to significantly elevate the mRNA expression of many 
chemokines in epididymal fat in WT mice, such as Mcp1 (5 fold), Mip1α (13 fold), 
Rantes (2 fold) and Mcp3 (28 fold), compared to animals on a chow diet. 
Interestingly, without a significant difference in total adiposity, Trpv4-/- mice 
showed a substantial decrease in the mRNA expression of Mcp1 (40%), Mip1α 
and Mcp3 (50%), relative to controls (Figure 3-3 A). Similarly, the induction of 
those genes in the subcutaneous fat in WT mice in response to HFD was also 
largely blunted in the Trpv4-/- mice (Figure 3-3 B). 
At 16 weeks of the HFD, compared to chow-fed animals, chemokine gene 
expression in epididymal fat continued to rise in WT mice:  Mcp1 (10 fold), Mip1α 
(72 fold), Rantes (4 fold) and Mcp3 (47 fold).  The expression of mRNAs for 
Mip1α and Vcam remained low (reduced by 70% and 30%) in the Trpv4-/- mice, 
compared to WT controls; the differences in Mcp1 and Mcp3 were blunted 
(Figure 3-3 A). Similar differences were observed in the inguinal adipose tissues 
(Figure 3-3 B). 
Trpv4-/- Mice Have Reduced Inflammation in Adipose Tissue and Improved 
Glucose Tolerance  
Obesity is associated with chronic “metainflammation” in adipose tissue 
(Hotamisligil, 2006). Cytokines such as TNFα (Hotamisligil et al., 1995; 
Hotamisligil et al., 1993) and IL-1β (Lagathu et al., 2006) are secreted from 
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Figure 3.3. Altered pro-inflammatory programs in Trpv4-/- adipose tissue. mRNA 
expression of chemokine/chemoattractant genes in epididymal (A) and 
subcutaneous (B) fat from WT and Trpv4-/- were analyzed  by QPCR, under all 
three diet conditions. Data are presented as mean ± sem. (n=9-13 in each group) 
Student’s t-test was used for single comparisons. * P<0.05, ** P<0.01, *** 
P<0.001, compared to control group. 
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immune cells in the inflamed adipose tissue (Weisberg et al., 2003; Xu et al., 
2003), and are believed to be a major contributor to systematic insulin resistance.  
To understand the biological impact of the changes in chemokine gene 
expression caused by TRPV4 deficiency (Figure 3-3 AB), we analyzed the 
expression of macrophage selective markers (F4/80, CD68 and CD11b) to 
quantify macrophage infiltration in Trpv4-/- and WT epididymal fat from all three 
diet groups: chow, 8-week HFD and 16-week HFD. We were interested to see if 
reduced chemotactic gene expression would result in decreased macrophage 
infiltration. As expected, HFD increased the expression of all three macrophage 
markers in WT adipose tissue (5-10 fold increased by 8 weeks, 10-30 fold 
increased by 16 weeks) (Figure 3-4 A), indicating that macrophages have been 
actively recruited into adipose tissue in response to high fat diet. Consistent with 
the reduction in chemokine expression, Trpv4-/- adipose tissue showed a 40% or 
60% reduction in the expression of all three macrophage markers mRNA after 8 
or 16 weeks of HFD, respectively (Figure 3-4 A). This suggests that there were 
significantly fewer macrophages being recruited into Trpv4-/- adipose tissue 
compared to WT controls. Indeed, histologic analysis also showed there were far 
fewer “crown-like-structures”, previously shown to represent macrophages in fat 
tissues (Cinti et al., 2005), in the Trpv4-/- epididymal fat compared to WT controls 
(Figure 3-4 B). 
Macrophages have been shown to be the major source of TNF-α and other 
inflammatory cytokines in inflamed adipose tissue. To further assess the 
inflammation associated with decreased macrophage infiltration, the mRNA  
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Figure 3-4. Trpv4-/- adipose tissue have less macrophage infiltration.  mRNA 
expression of three macrophage markers in epididymal fat from WT and Trpv4-/- 
mice on chow, 8-week HFD and 16-week HFD (A). H&E staining of epididymal 
adipose tissues from WT and Trpv4-/- mice after 16-week HFD (B), arrows 
indicates “crown like structures” (CLS) consisting of macrophages.  Data are 
presented as mean ± sem. (n=9-13 in each group) Student’s t-test was used for 
single comparisons. * P<0.05, ** P<0.01, *** P<0.001, compared to control group. 
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expression of Tnfα, a key cytokine for obesity-induced insulin resistance was 
measured. HFD significantly increased Tnfα mRNA in WT adipose tissue, while 
the induction was reduced by more than 30%-40% in adipose tissue from Trpv4-
/- mice (8 weeks HFD or 16 weeks HFD, respectively) (Figure 3-5 A).  
Furthermore, phosphorylation of serine 273 on PPARγ, a recently identified 
modification that is associated with obesity and insulin resistance (Choi et al., 
2010), was substantially attenuated in the Trpv4 -/- adipose tissue compared to 
WT controls (Figure 3-5 B) after 8 weeks or 16 weeks of high fat diet, strongly 
suggested that there was less inflammation and likely enhanced insulin 
sensitivity in the Trpv4-/- adipose tissue. 
Adipose tissue inflammation is associated with insulin resistance and could be 
represented as glucose intolerance in a standard glucose tolerance test. To 
assess if the reduction in TNFα and PPARγ phosphorylation has a physiological 
effect on insulin sensitivity, intraperitoneal glucose tolerance tests were first 
performed 7 weeks after HFD, when no difference in body weight had developed 
between the two genotypes. As shown in Figure 3-5 C, Trpv4-/- mice showed a 
small yet significant improvement in glucose tolerance as early as 7 weeks after 
high fat diet. As these mice continued on the diet (12 weeks), the relative 
improvement in glucose tolerance of mutants compared to controls became more 
apparent (Figure 3-5 D). 
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Figure 3-5. Trpv4-/- mice have less inflammation and improved glucose tolerance. 
mRNA expression Tnfα (A) in epididymal fat from WT and Trpv4-/- mice on chow, 
8-week HFD and 16-week HFD. (B) Western blot analysis of PPARγ serine-273 
phosphorylation and total PPARγ in epididymal fat after 8-week and 16-week 
HFD. Glucose tolerance tests, blood glucose levels were measured in 7 weeks 
(C) or 12 weeks (D) high fat-fed WT or Trpv4-/- mice, after overnight fasting (time 
0) and at the indicated times after intraperitoneal injection of glucose (1.5g/kg 
body weight for 7W-HFD and 1g/kg body for 12w-HFD). Data are presented as 
mean ± sem. (n=9-13 in each group) Two-way ANOVA was used for panel A, C, 
and D; others single comparisons were analyzed by student’s t-test. * P<0.05, ** 
P<0.01, *** P<0.001, n.s. not significant.  
  
A B
D
WT KO
pSer273 PPAR
8w-HFD
16w-HFD
pSer273 PPAR
PPAR
PPAR
Tnfa
R
el
at
ive
Ex
pr
es
sio
n
Chow 8-HF 16-HF
0
5
10
15 WT
KO**
C
7 Week HFD GTT
minutes after glucose injection
B
lo
od
G
lu
co
se
(m
g/
dl
)
0 20 40 60 90 12
0
0
200
400
600 W T
KO
p=0.003
12 Week HFD GTT
minutes after glucose injection
Bl
oo
d
G
lu
co
se
(m
g/
dl
)
0 20 40 60 90 12
0
0
200
400
600
WT
KO
p=0.01
72 
 
TRPV4 Deficiency Affects Adipocyte Pro-inflammatory Gene Program in a 
Cell-autonomous Manner 
Again, since Trpv4 -/- mice have whole-body TRPV4 deficiency, we asked if the 
phenotype observed in vivo was associated with cell-autonomous alterations in 
adipocyte cultures derived from these mice. To examine this, stromal-vascular 
cells from the adipose tissue of young, lean Trpv4 -/- and WT mice were isolated 
and stimulated to differentiate into adipocytes in vitro. After 8 days, greater than 
90% of the cells were fully differentiated. Importantly, the mRNA expression of 
pro-inflammatory chemokine/cytokines, such as Mcp1, Mip1α, Mcp3, Tnfα and 
Vcam were reduced by more than 80% in Trpv4-/- primary adipocytes (Figure 3-6 
A).  
Macrophages share many aspects of gene regulation with adipocytes. It is 
common that one molecule that regulates metabolic and/or inflammatory 
pathways in one cell type also regulates the same pathways in the other 
(Hotamisligil, 2006). Indeed, many of the chemokines we identified to be 
regulated by TRPV4 could also be secreted from macrophages, probably to a 
greater extent than they are secreted from the adipocytes. Moreover, in the case 
of pro-inflammatory signaling and immune cell recruitment, because 
macrophages are the cells that directly respond to the secreted chemokines, it is 
especially critical to know if  macrophages from the Trpv4-/- background have 
compromised pro-inflammatory secretion and/or response to those signals.  
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Figure 3-6. TRPV4 controls adipocyte pro-inflammatory gene program in a cell-
autonomous manner. (A) Chemokines and Tnfa mRNA expression in in vitro 
differentiated Trpv4-/- and WT primary adipocytes at the basal level. (B) 
Chemokines and Tnfa mRNA expression in peritoneal macrophages isolated 
from Trpv4-/- and WT animals. (C) Chemokines and Tnfα mRNA expression in 
bone marrow derived Trpv4-/- and WT macrophages, at basal and LPS 
stimulated levels. (C) Chemokines and Tnfα mRNA expression in bone marrow 
derived Trpv4-/- and WT macrophages, at basal and free fatty acid stimulated 
levels.  
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Primary peritoneal macrophages were first isolated from WT and Trpv4-/- mice. 
Their gene expression was examined as the basal tone of macrophage pro-
inflammatory program.  In contrast to the dramatic difference we observed in 
primary adipocytes, no significant difference in mRNA expression of chemokines 
(Mcp1, Mip1a, Rantes, Mcp3 and Vcam) or inflammatory cytokines such as Tnfa 
was observed between the macrophages from the two genotypes (Figure 3-6 B). 
To further examine the function of macrophages beyond the basal stage, we 
tested whether TRPV4 deficient macrophages could response normally to pro-
inflammatory stimulation, such as the typical M1 stimulation by LPS. We were 
also interested in stimulation with free fatty acids, which have been shown to be 
an important inflammatory signal in the context of obesity and diabetes. To do so, 
we derived macrophages from bone marrow precursors from WT and Trpv4-/- 
mice. In vitro differentiated macrophages were then stimulated with either LPS or 
FFA. As expected, LSP potently increased the expression of Mip1a (50 fold), 
Mcp3 (20 fold), Vcam (20 fold) as well as Tnfa (50 fold) mRNA in WT and Trpv4-
/- macrophages without significant difference (Figure 3-6 C), except there was a 
small decrease in Mcp1 induction observed in mutant macrophages. 
In the same time, free fatty acid (palmitate) also significantly induced the 
expression of these genes, although to a lesser extent (2-10 fold) compared to 
LPS treatment.  Again, no significant difference in terms of responses was 
observed between two genotypes; expect a small difference in basal Tnfa 
expression (Figure 3-6 D).  
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Taken together, these data indicate that TRPV4 controls pro-inflammatory gene 
programs in a cell autonomous manner in adipocytes, but does not appear to 
significantly affect the same pathway to macrophages. 
Pharmacological Inhibition of TRPV4 Represses the Pro-inflammatory 
Program and Improves Insulin Resistance 
We have demonstrated a negative role of TRPV4 in regulating pro-inflammatory 
program in white adipocytes in vivo and in vitro, mostly using genetic approaches. 
It is interesting to investigate if pharmacological tools that inhibit TRPV4 activity 
would therefore repress these pathways. This would be particularly useful as 
these kinds of agents could potentially be used in vivo to attenuate obesity-
related disorders. 
Compared to the other member of the TRPV family TRPV1, there are few 
specific antagonists available for TRPV4. GSK205 was reported to be a TRPV4 
specific antagonist with an IC50 around 1uM (Phan et al., 2009). We treated fully 
differentiated F442A adipocytes with 5uM GSK205 for 48 hours. While the fat 
differentiation was not altered per se, the antagonist treatment significantly 
suppressed pro-inflammatory genes such as Mcp1, Mip1a, Rantes and Mcp3 
(Figure 3-7 A) in adipocytes. 
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Figure 3-7. TRPV4 antagonist GSK205 represses pro-inflammatory gene 
expression and improves insulin resistance. 3T3-F442A adipocytes were treated 
with 10uM GSK205 or DMSO for 48 hours before mRNA expression of 
adipogenesis marker AP2 and pro-inflammatory chemokines were analyzed by 
QPCR (A). 7 days of B.I.D. 10mg/kg GSK205 by intraperitoneal injection did not 
significantly affect body weight of C57/B6 mice that have been on high fat diet for 
14 weeks (B). GSK205 treated HFD mice have reduced expression of 
chemokines and Tnfa mRNA in epididymal fat (C) and improved glucose 
tolerance (D). Data are presented as mean ± sem. (n=9-13 in each group) 
Student’s t-test was used for single comparisons. * P<0.05, ** P<0.01, *** 
P<0.001, compared to control group. 
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We were interested in testing whether using GSK205 in vivo could affect 
adipocyte gene expression and function. This is also a complex problem because 
many aspects of this compound could affect the interpretation of the results, such 
as the pharmacological kinetics, pharmacological dynamics, and the 
hydrophobicity of the compound.  Preliminary pharmacological kinetics studies 
indicated that GSK205 has a half-life of 2 hours after IP injection in mice plasma 
(unpublished result from communication with Dr. Patrick Griffin). Although the PK 
is unfavorable for long term treatment, as a proof-of-principle study, we were 
interested to see if GSK205 could function in animal models in a short term 
regimen. Wild-type C57/B6J mice were put on high fat diet for 14-15 weeks to 
induce obesity and insulin resistance. We dosed HFD mice with either GSK205 
(10mg/kg) or vehicle twice a day for 7 days. The compound was well tolerated 
over 7 days, as there was no obvious weight loss in the treated or vehicle control 
group (Figure 3-7 B). Interestingly, compared to the vehicle treated group, 
GSK205 treated mice showed significantly reduced mRNA expression of 
chemokines that have been shown to be regulated by TRPV4, such as Mip1a, 
Rantes and Vcam (Figure 3-7 C). Consistent with the decrease in these 
chemokines, mRNA expression of Tnfa was also significantly down-regulated in 
the treated mice. Other chemokines, including Mcp1 and Mcp3, together with the 
macrophage marker F4/80, showed a trend towards a decrease but did not reach 
statistical significance (Figure 3-7 C). 
The reduction of the macrophage marker F4/80 and Tnfa indicated that there 
was less inflammation in the GSK205 treated adipose tissue. We were interested 
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whether this change would have meaningful effect on systemic insulin resistance 
and metabolism. We performed intraperitoneal glucose tolerance tests in 
GSK205 or vehicle treated mice. Consistent with the changes in inflammation, 
GSK205 treated mice showed significantly improved glucose tolerance (Figure 3-
7 D).  
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Discussion 
By an unbiased microarray approach, we unexpectedly discovered that TRPV4 
potently regulated pro-inflammatory gene programs in adipocytes. The regulation 
is beyond the scope of affecting one or two genes, but broadly and profoundly 
controls the whole set of pro-inflammatory chemotactic genes. The positive 
regulation of those genes by TRPV4 seems to have a tonic, constitutive 
component, as the knockdown of the channel potently down-regulated the basal 
pro-inflammatory gene expression. Yet further activation of TRPV4 had additional 
merging concept of thermogenic “beige” adipocytes within white adipose tissue 
hints that there may be a place these tw 
As a positive regulator of the pro-inflammatory program, TRPV4 deficiency has 
substantial effects both in vitro and in vivo. In vivo, the effects seemed to be 
particularly apparent when animals were developing obesity and insulin 
resistance. In the context of high fat feeding and obesity, the loss of positive pro-
inflammatory TRPV4 signaling is clearly protective. The inflammation is largely 
attenuated in mice lacking TRPV4. At the same time, the associated insulin 
sensitivity was partially restored, independently of differences in adiposity.  
The most interesting observation is the preliminary therapeutic effects of the 
TRPV4 antagonist, GSK205. Unlike the genetic knockout model in which TRPV4 
was absent chronically and prior to the development of obesity, wild type 
subjects treated with GSK205 were first on high-fat diet for 14-15 week, by which 
time the obesity and insulin resistance were quite severe. Relatively short term 
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administration of GSK205 potently reversed the altered chemokine/cytokine 
expression in this chronic disease model and significantly improved glucose 
tolerance, an indication that insulin sensitivity in these mice was partially restored, 
despite the poor pharmacological properties of this drug. It is promising that, with 
a better developed compound that targets TRPV4, a better therapeutic effect 
could be achieved for obesity and metabolic diseases. 
Adipose inflammation is viewed as a complex interaction between adipocytes 
and surrounding cells, including macrophages, T-cells, NK cells and the 
vasculature. Many molecules that regulate pro-inflammatory signals in 
adipocytes have been shown to regulate the same signals in immune cells, 
particularly in macrophages, which shared largely overlapping gene regulation 
with adipocytes. Also, genes found to regulate pro-inflammatory pathways in 
adipocytes commonly regulate their responses to external stimulation, such as 
TNFα or other cytokines, rather than affecting basal gene expression. Therefore, 
the discovery of TRPV4’s role in controlling a basal, un-stimulated pro-
inflammatory gene program in a clonal adipocyte cell line is unusual and striking. 
The specificity of this regulation to adipocytes and the strong effects on basal 
gene expression, may suggest that the signaling from TRPV4 could be one of the 
very early alterations in an adipocyte in response to obesity that then initiates the 
recruitment of macrophages. More careful analysis throughout the time course of 
development of obesity in WT and Trpv4-/- mice will be required to further assess 
this hypothesis. 
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Materials and Methods 
Microarray Analysis 
Total RNA was isolated from indicated cell lines and used for microarray analysis. 
Array hybridization and scanning were performed by the Dana-Farber Cancer 
Institute Core Facility using Affymetrix Gene Chip Mouse Genome 430A 2.0 
arrays according to established methods. For up-regulated gene list, any gene 
whose expression was below 40 (Arbitrary Unit) in the experimental group was 
filtered; for down-regulated gene list, any gene whose expression was below 50 
(A.U.) in the control group was filtered. 
ELISA 
Overnight culture medium from fully differentiated adipocytes was used to 
measure chemokine concentrations. Millplex MAP Mouse Cytokine/Chemokine 
Panel (Millipore) was used according to manufacturer’s instruction for multiplex 
detection for MCP1, MIP1α, RANTES, MCP3 and TNFα.  
IP-Glucose Tolerance Test 
For glucose tolerance tests, animals were fasted overnight. The next morning, 
glucose levels in tail blood were measured with a standard glucometer prior to 
and at timed intervals following an intraperitoneal injection of 1.5 g/kg D-glucose. 
Blood glucose was measured 20, 40, 60, 90 and 120 minute after the glucose 
injection. 
Macrophage isolation and in vitro differentiation 
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Peritoneal macrophages were isolated three  days after thioglycollate challenge 
and cultured in RPMI, 10%FBS medium. For bone marrow (BM) derived-
macrophages, marrow was flushed from the femur and tibia, purified through 
Ficoll-Paque gradient (Amersham Biosciences), and cultured in DMEM 
containing 20% FBS and 30% L929 condition medium for 6 days. Differentiated 
macrophages were counted and re-plated in RPMI medium with 10% FBS for 
various experiments. For LPS stimulation, cells were pre-treated with IFN-γ 
(10ng/ml) overnight  and exposed to 100ug/ml LSP for 3 hours. For free fatty acid 
stimulation, cells were treated with 300uM palmitate for 3 hours.  
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Introduction 
Based on pharmacological and genetic evidence, we have demonstrated that the 
presence/activation of TRPV4 significantly affects the expression of genes that 
are important for oxidative metabolism, thermogenesis, and pro-inflammatory 
pathways in adipocytes. This regulation was identified at the gene expression 
level, and later we also showed that expression changes caused by TRPV4 
indeed have profound effects on cellular and whole-organism physiology, 
especially in Trpv4-/- mice challenged with a high fat diet.  
However, aside from knowing that TRPV4 is a non-selective ion channel that can 
be activated by a range of chemical and physical stimuli, the mechanism by 
which TRPV4 controls downstream gene regulation is still unclear. Ion channels 
have been intensively studied in excitable cells such as neurons or muscle cells, 
in which ion influx and the associated current is usually the direct functional 
readout of the channel activation. The lack of literature on TRPV signal-
transduction in non-excitable cells, for example, adipocytes, makes it difficult to 
identify the exact signal transduction cascades from the plasma membrane to 
any canonical transcriptional regulation.  
There are several signaling pathways known to control Pgc1a expression. 
TRPV4 is a calcium permeable channel and we have shown in a previous 
chapter that the activation of TRPV4 indeed leads to a rapid increase in total 
intracellular calcium. Calcium has powerful and broad signaling activity. It has 
been previous shown that in muscle cells, intracellular calcium can increase 
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Pgc1a expression, mainly through the activation of MAPK kinase p38 (Lin et al., 
2002). However, calcium is a positive regulator of Pgc1a in many cell types 
(Rohas et al., 2007). This model directly contradicts our finding that TRPV4, a 
calcium permeable channel, functions as a negative regulator of Pgc1a 
expression.  
cAMP and PKA are also known to regulate Pgc1a and particularly thermogenic 
gene expression. However, there are no reports suggesting that activation of 
TRPV4 in other cellular systems would lead to changes in cAMP level or PKA 
activation. Moreover, cAMP/PKA signaling is very important for activation of the 
thermogenic program in adipocytes, downstream of beta-adrenergic agonism. 
However, this is usually a very rapid and acute response. The observation that 
either antagonist inhibition or shRNA mediated knockdown took more than 24 
hours to have any effect in adipocytes, suggests that a slower and multi-step 
mechanism may be involved.  
On the other hand, the signaling pathways that control pro-inflammatory program 
have been intensively characterized in adipocytes. Stress-activated kinases have 
been shown to play very important roles in all stages of adipose inflammation 
and are believed to be a direct cause of insulin resistance by phosphorylating 
(therefore inhibiting) critical components in the insulin signaling cascades 
(Rudich et al., 2007). The pro-inflammatory signals they transduce also converge 
at NF-kB, which then translocate into nucleus to carry out the transcriptional 
regulation of inflammatory gene expression. Interestingly, in other cells types, it 
has been reported previously that MAP kinase ERK1/2 can be activated by 
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TRPV4 activation (Li et al., 2009; Li et al., 2011; Thodeti et al., 2009). This initial 
observation led us to investigate the role of MAP kinases in mediating signal 
transduction from TRPV4 to transcriptional control of the downstream genes. 
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Results 
TRPV4 Activation in Adipocytes Leads to Phosphorylation of ERK1/2 and 
JNK1/2 
It has been reported previously that the protein kinases ERK1/2 can be activated 
by TRPV4 signaling (Li et al., 2009; Li et al., 2011; Thodeti et al., 2009). We 
therefore examined TRPV4 agonism and activation of three MAP kinases that 
have been implicated in adipose biology: ERK1/2, JNK1/2 and P38MAPK. 
Addition of the TRPV4 agonist to 3T3-F442A adipocytes caused a rapid 
phosphorylation of ERK1/2 at sites known to reflect activation of this kinase 
(Figure 4-1). The activation appeared as soon as 15 minutes after the addition of 
the agonist. In contrast, no activating phosphorylation on P38 MAPK was 
detected with TRPV4 agonism. The β3-agonist CL316243 led to the expected 
P38MAPK activation in these cells, which was used as a positive control here 
(Cao et al., 2001) (Figure 4-1). In particular, the activation of ERK1/2 appeared to 
be dependent on TRPV4, as both basal and stimulated ERK1/2 phosphorylation 
was largely attenuated by the shRNA against TRPV4. Notably, 2 hours after 
agonist treatment, ERK phosphorylation in TRPV4 knockdown cells fully returned 
to baseline, whereas activation of ERK in control cells was sustained for at least 
24 hours. 
The addition of TRPV4 agonist also induced the potent activation of JNK1/2 as 
soon as 15 minutes, in control cells. However, the same activation is seen in 
TRPV4 knockdown cells, and lasted much longer in these cells than 
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 it did in control cells, suggesting that activation of JNK1/2 was likely not 
dependent on the presence of TRPV4. 
ERK1/2 Activation Primarily Mediates the Signal from TRPV4 Agonism to 
Gene Expression 
Inhibitors of MEK1/2 (U0126) and JNK (SP600125) were then used to determine 
if the activation of these two MAP kinases was required for the key TRPV4-
mediated gene regulation events. As shown in Figure 4-2 A, pretreatment of cells 
with U0126 and SP600125 blocked the TRPV4 agonist-induced phosphorylation 
of ERK1/2 and JNK1/2, respectively. Interestingly, U0126 effectively reversed the 
repression on Pgc1α caused by the agonist (Figure 4-2 B). In contrast, 
SP600125 had only a small effect.  
Concordantly, the induction of Mip1α and Cxcl1 by the TRPV4 agonist was totally 
abolished by pre-treating adipocytes with U0126. Pre-treating cells with 
SP600125 had no effect (Figure 4-2 B). These data strongly suggest that the 
ERK1/2 protein kinases mediate much of the effect of TRPV4 activation on both 
the repression of Pgc1α expression and the induction of many 
chemokines/cytokines in adipocytes. 
Calcium Influx is Required for TRPV4 Agonism to Activate ERK1/2 
We have demonstrated that the activation of ERK1/2 is required for TRPV4 to 
regulate both oxidative and pro-inflammatory gene expression. We were 
interested in the connection between TRPV4 agonism and ERK phosphorylation.  
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Figure 4-2. ERK1/2 mediates the signal transduction from TRPV4 to gene 
expression. (A) 3T3-F442A adipocytes were exposed to 100nM GSK1016790A 
for 15 minutes, with 45-minute pre-treatment of vehicle (GSK101+V), U0126 
(GSK101+U) or SP600125 (GSK101+SP), then cell lysates were analyzed by 
western blot. (B) mRNA expression of Pgc1α, Mip1α and Cxcl1 in these 
adipocytes were analyzed 48 hours after the treatment. (C) 3T3-F442A 
adipocytes with control shGFP or shTRPV4 were exposed to 100nM 
GSK1016790A or 50ng/ml TNFα for 15 minute, in regular DMEM or calcium-free 
DMEM. Cell lysates were analyzed by western blot. Data are presented as mean 
± sem. Student’s t-test was used for single comparisons. * P<0.05, ** P<0.01, *** 
P<0.001, n.s. not significant, compared to control group. 
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Because TRPV4 is a calcium permeable channel and the agonist we used here 
indeed causes a rise in intracellular calcium level, we wanted to understand if the 
calcium influx, mediated by TRPV4, is causing the activation of ERK1/2.  
Both control (shGFP) or TRPV4 knockdown 3T3-F442A adipocytes were 
exposed to 100nM TRPV4 agonist, in regular DMEM medium or in calcium-free 
DMEM. While the agonist treatment led to a strong phosphorylation of ERK1/2 
within 15 minute in regular DMEM, this activation was absent in adipocytes in the 
calcium-free medium (Figure 4-2 C). To rule out the possibility that a general 
defect in kinase activation was caused by calcium deprivation, TNFα, which is 
known to activate ERK1/2 in adipocyte was used as a positive control for the 
kinase activity. As shown in Figure 4-2 C, TNFα potently induced ERK1/2 
activation regardless of the presence of calcium in the medium. Importantly, in 
contrast to TNFα, the agonist was unable to activate ERK1/2 in the TRPV4 
knockdown cells under either media condition, again confirming that the 
activation was specific and dependent on TRPV4. Together, these results 
suggest that calcium influx from medium to cells is specifically required for the 
activation of ERK1/2 by TRPV4 agonism.  
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Discussion 
TRPV4 is known to be a calcium permeable but non-selective ion channel. 
Importantly, the mechanisms by which it can affect biological functions are not 
well understood. As we showed here, transport of calcium into cells is certainly a 
distinct mechanism, but because TRPV4 is not a calcium specific channel, it is 
also likely conducting other ions such as Mg or Mn, which may be important for 
its regulatory function. On the other hand, the presence of a rather large 
intracellular domain on TRPV4 (Phelps et al., 2010)  has also suggested that it 
could, in fact, also operate as a signal transducing protein. The TRPV proteins 
are best known as heat sensors and the receptor for capsaicin (TRPV1). It is 
interesting that TRPV4 has been shown to be activated by cell swelling (Liedtke 
et al., 2000; Strotmann et al., 2000) and by cellular stretch (Mochizuki et al., 2009; 
Thodeti et al., 2009). Since fat cells become very large in obesity, it is possible 
that this cellular distention activates TRPV4 and leads to the expression of the 
pro-inflammatory gene program as shown here.  
The precise mechanisms by which TRPV4 signals are obscure but it is clear that 
ERK activation is very important for the effects seen here on adipocytes. 
Interestingly, ERK1 has previously been suggested to play roles in both energy 
homeostasis and adipose inflammation. ERK1-/- mice have increased energy 
expenditure and are resistant to diet-induced obesity (Bost et al., 2005). In a 
separate study, ERK1 deficiency partially rescued leptin-deficient (ob/ob) mice 
from insulin resistance by decreasing adipose inflammation (Jager et al., 2011). 
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Several interesting questions remained here. The precise transcriptional 
components that connect ERK1/2 to the expression of Pgc1a and pro-
inflammatory genes are still not clear. What are the transcription factors that 
activate Pgc1a transcription and repress pro-inflammatory chemokines? Are 
those two programs driven by the same set of transcription factors or not? Or is 
the change in one program secondary to effects from changes in the other? 
Clearly, these are all important aspects that we need to understand better. NF-kB 
may be an interesting candidate downstream of ERK1/2 and potentially regulates 
both programs. Its role in promoting pro-inflammatory gene expression is well-
characterized. Intriguingly, there was report suggesting NF-kB can negatively 
modulate the expression of Pgc1a in muscle (Coll et al., 2006), particular in 
diabetic condition. Further investigation would be necessary to look into whether 
activation of TRPV4 could lead to an alteration in NF-kB activity, presumably via 
the change of ERK1/2 levels.  
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Materials and Methods 
Materials 
Antibody sources are as follows: anti-pERK1/2, ERK1/2, pJNK, JNK, pP38, P38 
(Cell Signaling). Forskolin, norepinephrine, GSK1016790A, AMG9810, AM251, 
insulin, dexamethasone, isobutylmethylxanthine and puromycin were from Sigma. 
U0126 and SP600125, TNFα were from Cell Signaling. Calcium free DMEM was 
made by adding 2.5uM EGTA into regular DMEM (Cellgro) then adjust the pH to 
7.2.  
 
 
 
 
 
 
 
Chapter 5: 
Conclusion and Discussion 
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Conclusion 
This thesis identified the TRP channel family member TRPV4, as a novel 
regulator of oxidative metabolism, thermogenesis and pro-inflammation gene 
programs in white adipocytes. A QPCR-based high-throughput small molecule 
screen initially identified a cannabinoid receptor 1 antagonist that induced Pgc1a 
mRNA expression by an off-target effect on TRPV4 activity.  We demonstrated 
that TRPV4 was a potent negative regulator of PGC1α, affecting mitochondrial 
biogenesis, OXPHOS and thermogenic capacity of white adipocytes in vitro.  
An unbiased microarray approach unexpectedly revealed that TRPV4 also 
positively controlled the expression of an array of pro-inflammatory genes, 
particularly chemokines. Loss and gain of function studies further demonstrated 
that TRPV4 functions as a central regulator of a broad chemotactic gene 
program in vitro.  
Both the thermogenic and pro-inflammatory aspects of TRPV4 function in 
adipocytes were further investigated in vivo using a genetic model of TRPV4 
deficiency. With minimal alteration observed in other oxidative tissues such as 
skeletal muscle and classical brown fat, Trpv4 -/- mice have higher thermogenic 
and brown fat characteristic gene expression in their white adipose tissues 
compared to wild type littermates. When challenged with a high fat diet, Trpv4 -/- 
mice have significantly higher energy expenditure than wild type controls without 
changes in food intake or movement, and were protected from diet induced 
obesity. These changes were consistent with the hypothesis that the altered 
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gene expression in white adipose tissues of Trpv4 -/- mice caused a shift in 
energy balance by increasing uncoupled respiration-mediated thermogenesis in 
these tissues. 
On the other hand, the up-regulation of a broad pro-inflammatory gene program 
in white adipose tissue caused by high fat diet was largely attenuated in the 
Trpv4 -/- mice. Importantly, this reduction seen in TRPV4-deficient mice 
appeared to be independent of the difference in obesity, which was also a result 
of TRPV4 deficiency. Consistent with the difference in pro-inflammatory gene 
expression, Trpv4 -/- adipose tissues have less macrophage infiltration and 
reduced inflammatory cytokine expression. Trpv4 -/- mice have improved glucose 
tolerance on high fat diet, suggesting they might be more insulin sensitive as a 
result of this attenuated inflammation.  
Finally, pharmacological manipulation of TRPV4 was preliminarily tested in vitro 
and in vivo. Gene expression changes in cultured adipocytes as well as in 
adipose tissue demonstrated that TRPV4 inhibition by drug treatment largely 
recapitulated the genetic loss of function of Trpv4. Consistent with this gene 
expression change, the TRPV4 antagonist improved diet-induced insulin 
resistance in animals. 
Connection between Adipose Thermogenesis and Inflammation 
Adipose cells play a number of key roles in systemic energy balance and 
metabolic regulation. First, white adipose cells are the primary depot for energy 
storage in mammals. This important function is highlighted in the tissue steatosis 
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and illnesses that occurs in individuals with lipodystrophy, a set of syndromes 
characterized by a localized or generalized deficiency in fat cells.  Second, in the 
context of obesity, where energy intake chronically outstrips energy expenditure, 
adipose cells become enlarged and adipose tissue becomes inflamed. This was 
first recognized as a greatly increased expression of TNFα and other cytokines in 
rodent models of obesity (Hotamisligil et al., 1993). While it was originally 
believed that fat cells themselves made these cytokines, it is now appreciated 
that most of the secretion of these molecules comes from immune cells, 
especially macrophages, that infiltrate adipose tissue in elevated numbers in 
obesity (Weisberg et al., 2003; Xu et al., 2003). Hence, a critical question is what 
are the physiological and pathological signals secreted by fat cells that regulate 
the infiltration and function of these immune cells. Finally, brown adipose cells 
are an important component of whole body energy homeostasis through the 
dissipation of stored chemical energy in the form of heat (thermogenesis). The 
role of brown fat as a defense against both hypothermia and obesity, at least in 
rodents, is now well established (Feldmann et al., 2009; Lowell et al., 1993). 
Adult humans have significant depots of brown fat but the contribution made by 
these deposits to total energy metabolism in man is not known. 
Thermogenesis and inflammation are ordinarily considered as two separate 
aspects of adipose biology. Although they are both important for obesity and 
metabolic diseases, there has been little data suggesting a regulatory linkage 
between the two programs in adipocytes. This is probably because, traditionally, 
thermogenesis was only thought to take place in the classic interscapular brown 
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fat, which is an anatomically separated organ from most white adipose tissues. 
Recently, the emerging concept of thermogenic “beige” adipocytes within white 
adipose tissue hints that there may be a place these two important functions 
could converge (Ishibashi and Seale, 2010). This was also suggested by the 
early observation that obesity and HFD led to decreased expression of the β3-
adrenegic receptor and impaired oxidative capacity in white adipose tissue 
(Fromme and Klingenspor, 2011; Lowell and Flier, 1997). Conversely, synthetic 
PPARγ ligand TZDs have both thermogenic and anti-inflammatory effects in 
adipose tissue, indicating these two pathways could be coordinately regulated 
(Petrovic et al., 2010) .  Interestingly, we showed that TRPV4 was a common 
cell-autonomous mediator for both thermogenic and pro-inflammatory programs 
in adipocytes, making TRPV4 the first genetic connection between these two 
important aspects of adipose biology. 
The Endogenous Activation of TRPV4 
TRPV4 is known to be a calcium permeable but non-selective ion channel. 
Importantly, the mechanisms by which it can affect biological functions are not 
well understood. Several questions remain: what is the biological function of 
TRPV4 in normal adipocytes? Or, what is TRPV4 “sensing” in adipocytes? Our 
data suggested TRPV4 was activated in adipocytes during the development of 
obesity. How does obesity change the activity of TRPV4?  It has been suggested 
that TRPV4 was activated by warm temperature and tonically active at 37°C 
(Guler et al., 2002; Watanabe et al., 2002). This is consistent with our data that 
the absence of TRPV4 had profound effects on basal gene expression in 
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adipocytes. However, our data also suggested TRPV4 activity could be furthered 
enhanced during the course of HFD; this can hardly be explained by the 
temperature alone. One explanation would be that certain metabolites associated 
with obesity, for example, lipid derivatives including endocannabinoids, might 
affect TRPV4 activity.  
It is interesting that TRPV4 has been shown to be activated by cell swelling 
(Liedtke et al., 2000; Strotmann et al., 2000) and by cellular stretch (Mochizuki et 
al., 2009; Thodeti et al., 2009). Based on this, it is interesting to hypothesize that 
the adipocyte hypertrophy might mechanically activate TRPV4. Adipose tissue 
expansion involves increases in both adipocyte number and cell size. The latter 
prevails in obesity and is associated with unfavorable metabolic consequences: 
large adipocytes usually have elevated pro-inflammatory adipokine production 
and are associated with more macrophage infiltration (Jernas et al., 2006; 
Murano et al., 2008; Skurk et al., 2007). It has also been noticed that smaller 
adipocytes are usually associated with higher thermogenic capacity and UCP1 
expression (Ghorbani and Himms-Hagen, 1997). Together, hypertrophy is 
associated with repressed thermogenesis but elevated pro-inflammatory gene 
expression; both could be resulted from TRPV4 activation. Currently, the 
mechanism through which hypertrophy alters adipocyte function is unknown, 
although it has been suggested that the increase of MCP1 expression in large 
adipocytes involved mechanical stress (Ito et al., 2007). Interestingly, it has been 
known that TRPV4 can be activated by mechanical stretch in other cells (Thodeti 
et al., 2009), followed by ERK1/2 activation as we observed in adipocytes after 
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TRPV4 agonism. Taken together, it is possible that activation of TRPV4 by cell 
membrane stretch may function as a cell size sensor that controls the 
downstream metabolic responses to obesity. 
In this regard, TRPV4 activation may provide a missing link between obesity and 
the initiation of “metainflammation” in adipose tissue. In positive energy balance, 
adipocytes first grow larger to accommodate the demand for lipid storage. When 
a certain size limit is reached, TRPV4 is activated by the membrane stretch.  
Similar to the development of atherosclerosis, the initial purpose of this activation 
might be to recruit macrophages to clear the lipid overflow in adipose tissue.  
However, if the positive energy balance persists, the pro-inflammatory signals get 
amplified in a pathological vicious cycle that eventually leads to chronic 
“metainflammation” in adipose tissue.   
TRPV4 in Other Tissues 
Our data suggests that pharmacologic inhibition of TRPV4 in adipocytes may 
lead to an increase in energy expenditure and a reduction in adipose tissue 
inflammation; both could potentially provide therapeutic benefits for obesity and 
metabolic diseases. Although TRPV4 is expressed at high levels in fat (Liedtke et 
al., 2000), it is also expressed in many other tissues. Hence the therapeutic value 
of TRPV4 antagonists in humans may depend on the function of this protein in 
other tissues (Everaerts et al., 2010). In this regard, it is interesting that a very 
recent study of Trpv4 KO mice has also shown a resistance to diet induced 
obesity, though this paper did not examine adipose tissues in detail (Kusudo et 
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al., 2011). Instead they showed alterations in muscle biology and fiber-type 
switching in the soleus muscle. It is not clear how this could affect whole body 
energy balance and obesity, but the role of TRPV4 in multiple tissues will be 
important for future studies.  
It should also be taken into consideration that TRPV4 might have profound role in 
bone development and remodeling. It has been reported that the calcium influx 
mediated by TRPV4 was important for osteoclast differentiation. Trpv4 -/- mice 
developed mild osteopetrosis with aging, likely due to a defect in bone 
reabsorption (Masuyama et al., 2008). More importantly, it is critical to 
understand the nature of the TRPV4 mutations that cause skeletal abnormalities 
in humans before developing strategies to manipulate TRPV4 activity for 
metabolic diseases. 
Other closely related TRPVs, such as TRPV1, may also regulate one or both 
pathways controlled by TRPV4 in adipocytes. Indeed, our results suggest TRPV1 
might have a similar function as TRPV4 in adipocytes, whereas TRPV2 is likely 
to have an opposite function. Nonetheless, the fact that the genetic ablation of 
Trpv4 had a cell-autonomous effect on both the thermogenic and pro-
inflammatory programs in adipocytes in vivo makes TRPV4 a very promising 
pharmaceutical target for treating obesity and type 2 diabetes. 
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